Antimicrobial drug sensitivity

Through FASTinov assay and flow cytometry, combined with fluorescent probes and control reservoir technology, the sensitivity of microorganisms to antibiotics is quickly evaluated, solving the problem of time-consuming and low accuracy of existing testing methods, and achieving rapid and accurate Antimicrobial sensitivity testing supports more effective treatment and public health management.

CN118900918APending Publication Date: 2024-11-05FASTINOV SA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380027779.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-02-10
Filing Date
2023-02-09
Publication Date
2024-11-05

AI Technical Summary

Technical Problem

The existing antimicrobial sensitivity test methods take a long time and cannot quickly provide information about bacterial sensitivity to antibiotics, resulting in serious antimicrobial resistance problems. Molecular testing cannot fully understand the sensitivity of bacteria, and there is a false negative. and false negative errors.

Method used

Using the FASTinov assay, the microorganisms were isolated in positive biological samples, the damage to the cells was evaluated using fluorescent probe staining and flow cytometry, and the sensitivity and accuracy of the assay were improved in combination with positive and negative control reservoirs to quickly obtain microbial pairs. Antibiotic sensitivity phenotype.

Benefits of technology

It achieves accurate antimicrobial sensitivity reports within recording time, supports targeted therapy, can detect multidrug-resistant microorganisms, reduce treatment delays, and improve treatment effectiveness and public health safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118900918A_ABST
    Figure CN118900918A_ABST
Patent Text Reader

Abstract

The present invention relates to methods and kits for detecting and determining the sensitivity of microorganisms to therapeutic agents. The invention relates to rapid determination of the sensitivity of bacteria to antibiotics. The invention also extends to methods of preparing samples and extracting microorganisms from biological samples, as well as methods of identifying microorganisms and kits and plates specially designed for determining the sensitivity of extracted microorganisms to antimicrobial drugs. The invention is particularly useful in clinical diagnosis and veterinary medicine.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The present invention relates to antimicrobial susceptibility, and methods and kits for detecting and determining the sensitivity of microorganisms to therapeutic agents, particularly but not exclusively for rapidly determining the sensitivity of bacteria to antibiotics. The invention also extends to methods of preparing samples and extracting microorganisms from biological specimens, as well as methods of identifying microorganisms and kits and plates specifically designed for determining the susceptibility of extracted microorganisms to antimicrobial drugs. The invention is particularly useful in clinical diagnostics and veterinary medicine.

[0002] Antimicrobial resistance (AMR) is a growing global threat to human, animal and environmental health. One of the main causes of AMR includes overuse of antibiotics in animals and humans, and the release of non-metabolized antibiotics or their residues into the environment through urine or feces.

[0003] The antimicrobial susceptibility profile of a microorganism is usually determined by evaluating its ability to grow in the presence of different antimicrobials, which usually takes about two days from the collection of the biological sample to the determination of the susceptibility profile. By applying broad-spectrum antimicrobials, epidemiology-based treatment is applied in most hospitals around the world because these processes take a long time. This in turn has triggered antimicrobial resistance, leading to serious personal and public health threats.

[0004] Therefore, there is an urgent need for rapid antimicrobial susceptibility tests (ASTs) that can provide relevant and useful information in a timely manner to enable optimal implementation of antimicrobial therapy based on scientific reports. In response to this growing need, several approaches, including molecular-based tests, have been developed over the years. Although molecular tests may have the advantage of directly screening polymicrobial samples for selected antimicrobial resistance mechanisms, their role in patient care is very limited because they cannot provide information on the susceptibility of bacteria to certain antimicrobial drugs.

[0005] Furthermore, molecular testing can only assess resistance mechanisms, and there is documented evidence of discrepancies between genotypic and phenotypic test results. Antimicrobial resistance is too complex to rely on this approach to gain a truly comprehensive understanding of the problem.

[0006] Therefore, to overcome the limitations of existing AST, the inventors have developed a new, highly innovative method, called the "FASTinov assay", and a corresponding platform, which allow the provision of AST reports to clinicians directly from positive biospecimens in record time, thereby enabling targeted antimicrobial therapy rather than the use of broad-spectrum antimicrobial drugs [6, 7, 8]. The present invention also enables the detection of multidrug-resistant microorganisms [5], which in turn allows for more aggressive treatment to be implemented in the shortest possible time, thereby avoiding their spread in hospital wards, throughout the hospital or beyond. Therefore, the invention described herein has the potential to revolutionize the treatment of infected patients, with significant advantages for both patients and society.

[0007] The present invention represents a significant improvement and development on the previous susceptibility testing method and panel described by the inventors in WO2012 / 164547A1 [1]. The inventors' new method involves an innovative sample preparation and extraction process designed to isolate microorganisms from human or animal cells and to separate fragments from positive biological samples. The isolated microorganisms are then incubated with an antimicrobial drug for a short period of time and then stained with an optimized fluorescent probe. The damage caused by the drug to the cells is then assessed by multi-parameter analysis using flow cytometry. Since the test is growth-independent, results can be obtained in record time.

[0008] Flow cytometry has proven to be a powerful tool in several disciplines such as hematology and cytopathology, and its application in microbiology is becoming more and more widespread, with great potential. In fact, using flow cytometry, it is possible to differentiate cell microbiota in terms of sensitive and resistant phenotypes in a very short time frame. In fact, the use of the right fluorescent dyes at a defined wavelength allows the rapid detection and quantification of antimicrobial effects using software that allows the analysis of large amounts of biological data, including cell size and complexity.

[0009] Thus, in a first aspect of the present invention, there is provided a method for determining the sensitivity phenotype of a microorganism present in a biological sample to at least one therapeutic agent, the method comprising:

[0010] (i) introducing a biological sample including a microorganism into:

[0011] (a) one or more first test reservoirs,

[0012] (b) one or more second positive control reservoirs, and

[0013] (c) one or more third negative control reservoirs, wherein the negative control reservoirs comprise non-viable microorganisms;

[0014] (ii) contacting the biological sample in the one or more first test reservoirs with at least one therapeutic agent;

[0015] (iii) contacting the biological sample in one or more of the first reservoir, the second reservoir, and the third reservoir with at least one fluorescent marker; and

[0016] (iv) performing fluorescence analysis to obtain one or more fluorescence parameters of the biological sample in each reservoir,

[0017] Wherein the sensitivity phenotype of the microorganism to at least one therapeutic agent is obtained by comparing one or more fluorescence parameters between the reservoirs.

[0018] Advantageously, the inventors have found that in this method, the use of a third negative control reservoir in addition to the second positive control reservoir significantly improves the sensitivity of the assay, thereby producing an effective and accurate sensitivity phenotype reading, providing the best treatment for the patient. This is because the use of positive and negative controls in addition to the test sample ensures that only live microorganisms are considered in the sensitivity phenotype assessment assay. Non-live (i.e., dead) microorganisms cannot respond to therapeutic agents, so if they are included in the sensitivity phenotype assessment, such non-live microorganisms may mistakenly become resistant to all therapeutic agents, which corresponds to a false negative or a major error, resulting in the implementation of the wrong subsequent treatment.

[0019] Thus, preferably, the one or more third negative control reservoirs comprise non-viable or dead microorganisms and the one or more second positive control reservoirs comprise viable or alive microorganisms.Preferably, the one or more first test reservoirs comprise viable or alive microorganisms.

[0020] Preferably, the one or more first test reservoirs comprise at least 60%, 70% or 80% viable cells. More preferably, the one or more first test reservoirs comprise at least 85%, 90% or 95% viable cells. More preferably, the one or more first test reservoirs comprise at least 96%, 97%, 98%, 99% or 100% viable cells. Preferably, the one or more first test reservoirs comprise at least 10 5 CFU / ml of viable cells, or at least 10 6 CFU / ml of viable cells, or at least 10 7 CFU / ml of viable cells.

[0021] Preferably, the one or more second positive control reservoirs comprise at least 60%, 70% or 80% viable cells. More preferably, the one or more first second positive control reservoirs comprise at least 85%, 90% or 95% viable cells. More preferably, the one or more second positive control reservoirs comprise at least 96%, 97%, 98%, 99% or 100% viable cells. Preferably, the one or more second test reservoirs comprise at least 10 5 CFU / ml of viable cells, or at least 10 6CFU / ml of viable cells, or at least 10 7 CFU / ml of viable cells.

[0022] Preferably, one or more third negative control reservoirs comprise at least 60%, 70% or 80% non-viable cells. More preferably, one or more third negative control reservoirs comprise at least 85%, 90% or 95% non-viable cells. More preferably, one or more third negative control reservoirs comprise at least 96%, 97%, 98%, 99% or 100% non-viable cells.

[0023] The cells in the one or more third negative controls can be rendered nonviable by exposure to a cell-killing agent. Preferably, the one or more third negative control reservoirs include a cell-killing agent. Preferably, the cell-killing agent is selected from the group consisting of ethanol, 2-phenoxyethanol, citric acid, and benzydamine hydrochloride. Most preferably, the cell-killing agent is benzydamine hydrochloride.

[0024] The inventors have previously demonstrated that benzydamine hydrochloride rapidly kills bacteria

[14] and fungi

[13] through cell membrane damage. The purpose of this control is to ensure that the fluorescent probe is active and has maximum effect when the cells are killed by benzydamine hydrochloride. Therefore, in a preferred embodiment, the cells in one or more third negative control reservoirs are rendered nonviable by exposure to benzydamine hydrochloride.

[0025] If at least one fluorescent marker is absent or poorly expressed, the effect of the therapeutic agent on the microorganism will be difficult, if not impossible, to assess. Therefore, the use of a negative control reservoir improves the accuracy of the method. Moreover, the inventors surprisingly found that in the method of the present invention, the use of positive and negative controls can identify different levels of sensitivity phenotypes to at least one therapeutic agent, i.e., sensitive, intermediate or resistant to at least one therapeutic agent.

[0026] Thus, in one embodiment, the sensitivity phenotype may be sensitive, intermediate or resistant.

[0027] Fluorescence analysis can be performed by flow cytometry. Accurate measurement of fluorescence signals by flow cytometry may be hampered by background fluorescence caused by the autofluorescence of the microorganism itself. To overcome this problem, the inventors have advantageously found that the use of a fourth autofluorescence control reservoir comprising microorganisms that have not been treated with a therapeutic agent and have not been stained with a fluorescent marker enables the evaluation of the autofluorescence of the microorganism itself. When this is taken into account when analyzing the fluorescence parameters used to determine the sensitivity spectrum of the microorganism, the removal of the autofluorescence background significantly improves the accuracy of the test.

[0028] Thus, in one embodiment, the method further comprises introducing the biological sample into one or more fourth autofluorescence control reservoirs, wherein neither the therapeutic agent nor the fluorescent marker is added to the reservoir. In other words, the one or more fourth autofluorescence control reservoirs do not include the therapeutic agent or the fluorescent marker.

[0029] Preferably, the one or more fourth autofluorescence control reservoirs include live or viable microorganisms. Preferably, the one or more fourth autofluorescence control reservoirs include at least 60%, 70% or 80% viable cells. More preferably, the one or more fourth autofluorescence control reservoirs include at least 85%, 90% or 95% viable cells. More preferably, the one or more fourth autofluorescence control reservoirs include at least 96%, 97%, 98%, 99% or 100% viable cells. Preferably, the one or more fourth autofluorescence control reservoirs include at least 10 5 CFU / ml of viable cells, or at least 10 6 CFU / ml of viable cells, or at least 10 7 CFU / ml of viable cells.

[0030] The inventors surprisingly discovered that the sensitivity of the method is increased when the microorganisms are isolated or separated from any host cells present in the biological sample (i.e., from the subject / patient from which the sample was collected) prior to introduction into the test and control reservoirs. Without a highly pure and concentrated sample of microbial cells (without any host cells in the test subject), accurate flow cytometry readings and analysis will be difficult because the host cells themselves will produce non-specific fluorescence that will interfere with the analysis of the fluorescence produced by the microorganisms.

[0031] Therefore, in a preferred embodiment, the method further comprises a sample preparation step. Preferably, the sample preparation step comprises extracting and purifying the microorganism from host cells and / or debris also present in the biological sample before introducing the microorganism into one or more first reservoirs, second reservoirs, third reservoirs and / or optional fourth reservoirs.

[0032] The inventors have successfully demonstrated for the first time that density gradient solutions (such as histopaque (RTM) provided by Sigma) that can separate microorganisms from host cells and debris by centrifugal gradients are more effective than standard physical separations used in the prior art. This new method is applicable to all types of biological samples without affecting the physical and physiological functions of the microorganisms and thus the fluorescence analysis.

[0033] Other methods for directly identifying microorganisms from biological samples have been described in the art. However, these methods are limited to the use of hemolytic agents, and the use of density gradient solutions, such as histopaque (RTM), to extract and purify microorganisms (such as bacteria) from biological samples has never been described in clinical microbiology methods. The new method developed by the inventors allows purified microorganisms to accumulate at the bottom of a tube or vial, while cell debris and host cells bound to histopaque (RTM) accumulate at the top of the tube.

[0034] In addition, the new method developed by the inventors enables the use of the same sample for MALDI-TOF identification of bacteria causing infection. Typically, the prepared sample must undergo additional processing methods before being processed for MALDI-TOF bacterial identification. However, with the inventors' new sample preparation method, the sample is automatically ready for MALDI-TOF identification without any further processing, thereby saving time, which is critical in a clinical microbiology laboratory environment (where timely diagnosis has a huge impact on the patient's prognosis).

[0035] Therefore, the sample preparation step preferably includes purifying the microorganism from the biological sample before introducing the microorganism into each of the first reservoir, the second reservoir, the third reservoir and / or the optional fourth reservoir. The sample preparation step may include:

[0036] (i) obtaining a biological sample including a microorganism; and

[0037] (ii) contacting the biological sample with a density gradient solution to purify the microorganisms.

[0038] Preferably, the density gradient solution is histopaque (RTM). It is preferably pure, without any dilution. Histopaque (RTM) is a density gradient cell separation medium, including Ficoll and sodium diatrizoate. Most preferably, the biological sample and the density gradient are present in a ratio of about 1:1. The sample preparation step may include extracting microorganisms from the biological sample.

[0039] After the step of contacting the biological sample with the density gradient solution, the sample preparation step preferably comprises centrifuging the sample, preferably for at least one minute, preferably at about 13,000 rpm. The sample preparation step comprises resuspending the resulting precipitate (including the purified microorganisms) in a culture medium. The culture medium may preferably be a cation-adjusted broth, optionally about 1 ml of sterile filtered Mueller Hinton II cation-adjusted broth.

[0040] In some embodiments, the sample preparation step may include contacting the biological sample with a hemolytic agent prior to contacting the biological sample with the density gradient solution. Preferably, the hemolytic agent is configured to lyse any contaminating cells in the sample, such as contaminating host cells from the host from which the sample was collected, or debris present in the environmental sample.

[0041] The inventors have found that in embodiments where the biological sample may comprise blood, preferably a blood culture, the use of a hemolytic agent is particularly advantageous. Figure 1 Scheme B disclosed in shows a preferred embodiment of the sample preparation step of the method when the biological sample is a blood sample.

[0042] In one embodiment, the hemolytic agent can be Triton TM X-100 (commonly known as Triton X-100). TM X-100 is a common nonionic surfactant and emulsifier, often used in biochemical applications to solubilize proteins. It is considered a relatively mild and non-denaturing detergent. It is used to lyse cells to extract proteins and organelles. It can also permeabilize living cell membranes for transfection, or for DNA extraction.

[0043] Preferably, Triton X-100 is used at a concentration between 0.1% and 3% (v / v), or between 0.2% and 2.5% (v / v), or between 0.3% and 2% (v / v), or between 0.4% and 1% (v / v), preferably about 0.5% (v / v). Preferably, the biological sample is contacted with the hemolytic agent (preferably Triton X-100) for at least 1 minute, 2 minutes or 5 minutes. Preferably, the biological sample is contacted with the hemolytic agent (preferably Triton X-100) for less than 2 hours, 1 hour, 30 minutes or less than 15 minutes. This step can be performed at room temperature. Therefore, preferably, the sample preparation step includes contacting the biological sample with the hemolytic agent for five minutes at room temperature.

[0044] In another preferred embodiment, the hemolytic agent is Tergitol TM 15-S-9 (commonly known as Tergitol): Tergitol is a secondary alcohol polyoxyethylene ether and a linear nonionic surfactant.

[0045] Preferably, Tergitol is used in a concentration between 2.5% and 25% (v / v), or between 3% and 22% (v / v), or between 4% and 20% (v / v), or between 5% and 18% (v / v). More preferably, Tergitol is used in a concentration between 6% and 16% (v / v), or between 7% and 14% (v / v). Most preferably, Tergitol is used in a concentration between 8% and 12% (v / v), or between 9% and 11% (v / v), preferably about 10% (v / v). Preferably, the biological sample is contacted with Tergitol and mixed (preferably by vortexing).

[0046] Advantageously, Tergitol has a better safety profile, as it is not included in the REACH (Registration, Evaluation, Authorization and Restriction of Chemicals) list of hazardous substances. Moreover, Tergitol requires only a short incubation time and thus ensures a timely diagnosis. In addition, Tergitol also works for MALDI-Tof recognition, which is advantageous. Tergitol also ensures a higher purity of the sample to be analyzed. Therefore, the use of Tergitol is compatible with flow cytometry (FC) analysis, which requires extremely high purity cell suspensions.

[0047] After contacting the biological sample with the hemolytic agent and before contacting the biological sample with the density gradient solution, and before the step, the sample preparation step preferably includes centrifuging the sample, preferably for at least one minute, preferably at about 13000 rpm. Preferably, the sample preparation step then includes resuspending the resulting precipitate (with the microorganisms). Preferably, the precipitate is resuspended in a saline solution, optionally about 0.05 ml to 2 ml, 0.01 ml to 1 ml, or 0.25 ml to 0.75 ml of a sterile filtered saline solution. Most preferably, the precipitate is resuspended in 0.5 ml of a sterile filtered saline solution.

[0048] The hemolytic agent used in the extraction method allows the lysis of the host's cells, particularly red blood cells, and potential debris that may be present in the biological sample, while retaining the cells of the microorganism. The sample preparation protocol described herein allows the purified microorganisms to accumulate toward the bottom of the tube, while the cell debris and host cells bound to the density gradient solution accumulate toward the top of the tube.

[0049] The sample preparation step can also be included in the biological sample including the microorganism before being introduced into each of the first reservoir, the second reservoir, the third reservoir and / or the optional fourth reservoir, identifying the microorganism. Genetic methods, microarrays, physical methods and / or mass spectrometry can be used to identify the microorganism. The genetic method can be quantitative polymerase chain reaction (PCR), immune PCR or its combination. The microarray can be a DNA microarray, a protein microarray, an antibody microarray or its combination. The physical method can be infrared spectroscopy and Raman spectroscopy or laser induced breakdown spectroscopy (LIBS). Mass spectrometry can be carried out by ICP mass spectrometer, DART mass spectrometer or MALDI-TOF Brucker.

[0050] Preferably, the identification of the microorganism is performed using mass spectrometry. Most preferably, the mass spectrometry is performed using a MALDI-TOF, for example from a manufacturer such as Brucker.

[0051] Advantageously, if Fig. 6A and Figure 6B As shown, the inventors have discovered that subsequent identification of microorganisms using samples extracted and purified in the above-mentioned sample preparation steps can quickly produce (i.e., within only a few hours) excellent results and outstanding identification accuracy equivalent to standard microbial colonies without the need for the additional step of generating colonies from overnight cultures.

[0052] Thus, in one embodiment, identification of microorganisms is performed using a sample that has been purified using the sample preparation steps described above.Preferably, the purified sample is substantially dried prior to exposure to the mass spectrometer.

[0053] Therefore, the sample preparation step may also include an additional centrifugation cycle to dry the precipitate. The additional centrifugation cycle may be run between 5 seconds and 5 minutes, between 10 seconds and 5 minutes, between 30 seconds and 5 minutes, between 30 seconds and 4 minutes, between 30 seconds and 3 minutes, between 30 seconds and 2 minutes, between 30 seconds and 1.5 minutes, or between 30 seconds and 1 minute. Preferably, the additional centrifugation cycle may be run for at least 1 minute.

[0054] Additional centrifugation steps may be run at between 5000 rpm and 20000 rpm, between 10000 rpm and 18000 rpm, between 12000 rpm and 16000 rpm, or between 13000 rpm and 15000 rpm.

[0055] The sample preparation step may further include drying the precipitate resulting from the additional centrifugation cycle. The resulting precipitate may be dried at between 0°C and 40°C, or between 30°C and 40°C, or between 35°C and 40°C. The resulting precipitate may be dried at 4°C, room temperature, or 37°C.

[0056] Other sample purification methods for identifying microorganisms are also contemplated within the scope of the present invention for identifying microorganisms. These include, for example, methods recommended by mass spectrometer manufacturers.

[0057] The inventors have successfully demonstrated that the novel sample preparation steps described above advantageously provide a very rapid one-step method to obtain highly purified samples for efficient identification of microorganisms and subsequent testing of their susceptibility to antimicrobial drugs in a time-efficient manner.

[0058] The biological sample can be of human, animal or environmental origin. In embodiments where the biological sample is of human or animal origin, the sample is preferably a biological sample taken from a test subject. Therefore, the method for determining the microbial sensitivity phenotype in the sample is preferably performed in vitro or ex vivo. The sample can include tissue, blood, plasma, serum, spinal fluid, urine, bronchial secretions, cerebrospinal fluid, sweat, saliva, sputum, tears, sucking milk, prostatic fluid, semen, vaginal fluid, feces, cervical scrapings, amniotic fluid, intraocular fluid, mucus, moisture in breath, animal tissue, cell lysate, tumor tissue, hair, skin, oral scrapings, nails, bone marrow, cartilage, prions, bone meal, earwax or a combination thereof. The sample can be a biopsy. Preferably, the sample is blood. Preferably, the sample is saliva.

[0059] In a preferred embodiment, the biological sample of human origin is a urine sample or a blood sample. A blood sample is preferred. Most preferably, the sample is a blood culture.

[0060] In embodiments where the biological sample is of environmental origin, the sample is preferably selected from the group consisting of soil, water and plant debris.

[0061] Prior to subjecting the biological sample to analysis by the methods of the present invention, the biological sample may be cultured or uncultured. Advantageously, the ability to process the biological sample when uncultured significantly reduces experimental time and prevents unnecessary sample culture steps. Therefore, preferably, the biological sample is uncultured.

[0062] The biological material may be an aerobic or anaerobic sample. Thus, the sample may comprise an aerobic blood culture or an anaerobic blood culture.

[0063] Prior to fluorescence analysis, one or more of the first reservoir, the second reservoir, the third reservoir and / or the optional fourth reservoir may be incubated between 0° C. and 40° C., between 20° C. and 40° C., between 22° C. and 40° C., between 24° C. and 40° C., between 26° C. and 40° C., between 28° C. and 40° C., between 30° C. and 40° C., between 32° C. and 40° C., between 34° C. and 40° C., between 36° C. and 40° C., or between 38° C. and 40° C. One or more of the first reservoir, the second reservoir, the third reservoir and / or the fourth reservoir may be incubated between 0° C. and 40° C., or between 30° C. and 40° C., or between 35° C. and 40° C., or at about 0° C., 4° C., room temperature or 37° C. Preferably, one or more of the first reservoir, the second reservoir, the third reservoir and / or the fourth reservoir is incubated at 37° C.

[0064] Prior to the fluorescence analysis, one or more of the first reservoir, the second reservoir, the third reservoir and / or the optional fourth reservoir may be incubated with or without shaking. Preferably, the biological sample is incubated with shaking.

[0065] Prior to fluorescence analysis, one or more of the first reservoir, the second reservoir, the third reservoir and / or the optional fourth reservoir may be incubated for up to 6 hours, 5 hours, 4 hours, 3 hours, 2 hours, 1 hour or 30 minutes. Preferably, the biological sample is incubated for about 1 hour.

[0066] After this incubation step, one or more of the first reservoir, the second reservoir, the third reservoir and / or the fourth reservoir is preferably subjected to a fluorescence analysis step.

[0067] Microorganisms can be bacteria, viruses, fungi or protozoa.

[0068] In a preferred embodiment, the microorganism is a bacterium. The bacterium can be a gram-negative bacterium, a gram-positive bacterium, or a bacterium having both gram-negative and gram-positive characteristics. The bacterium can be aerobic or anaerobic. In a preferred embodiment, the microorganism is an aerobic bacterium.

[0069] Preferably, the Gram-negative bacteria may be a Gram-negative bacillus selected from the group consisting of Escherichia coli ATCC 25922, Escherichia coli ATCC 8739, Escherichia coli ATCC 35218, Escherichia coli BAA2425, Klebsiella pneumoniae ATCC 13443, Klebsiella pneumoniae BAA1705, Klebsiella pneumoniae ATCC 700603, Klebsiella pneumoniae BAA1706, Enterobacter aerogenes ATCC 13048, Serratia marcescens ATCC 14756, Providencia rattii BAA 2525, Pseudomonas aeruginosa 27853, Pseudomonas aeruginosa BAA2108, and Acinetobacter baumannii BAA 1709.

[0070] Preferably, the Gram-positive bacteria may be Gram-positive cocci in a grape-like cluster selected from the group consisting of Staphylococcus aureus 29213, Staphylococcus aureus 43300, Staphylococcus aureus 700698 and Staphylococcus epidermidis 35984.

[0071] More preferably, the Gram-positive bacteria may also be Gram-positive cocci in a chain selected from the group consisting of Enterococcus faecalis 29212, Enterococcus faecalis 51299, Enterococcus faecium 700221, Enterococcus casei 700668 and Enterococcus gallinarum 49608.

[0072] The bacteria may also be selected from the group consisting of: Neisseria meningitidis, Streptococcus pneumoniae, Streptococcus pyogenes, Moraxella catarrhalis, Bordetella pertussis, Burkholderia spp. (e.g., Burkholderia mallei, Burkholderia pseudomallei, and Burkholderia spp.), Haemophilus influenzae, Clostridium tetani (tetanus), Clostridium perfringens, Clostridium botulinum, Corynebacterium diphtheriae (diphtheria), Legionella pneumophila, Coxiella burnetii, Brucella spp. (e.g., Brucella abortus, Brucella canis, Brucella melitensis, Brucella suis, Brucella pyogenes, and Brucella fin-shaped Brucella), Francisella (e.g., Francisella novicida, Yersinia mirage, and Francisella tularensis), Streptococcus agalactiae, Neisseria gonorrhoeae, Chlamydia trachomatis, Treponema pallidum (syphilis), Haemophilus ducreyi, Helicobacter pylori, Staphylococcus saprophyticus, Yersinia enterocolitica, Bacillus anthracis (anthrax), Yersinia pestis (plague), Mycobacterium tuberculosis, Rickettsia, Listeria, Chlamydia pneumoniae, Vibrio cholerae, Salmonella enterica serovar Typhi (typhoid), Borrelia burgdorferi, Porphyromonas, Streptococcus pneumoniae, Mycobacterium tuberculosis, and Haemophilus influenzae.

[0073] In another embodiment, the microorganism can be a virus. The virus can be selected from the group consisting of: orthomyxovirus, paramyxoviridae, metapneumovirus and measles virus, pneumovirus, paramyxovirus, poxviridae, parapneumovirus, measles virus, picornavirus, enterovirus, bunyavirus, herpesvirus, nairovirus, hepatovirus, enveloped virus, alphavirus, arterivirus, flavivirus, pestivirus, hepadnavirus, rhabdovirus, caliciviridae, coronavirus, retrovirus, reovirus, parvovirus, hepatitis delta virus (HDV), hepatitis E virus (HEV), human herpesvirus and papovavirus.

[0074] Orthomyxoviruses can be influenza A, B and C. Paramyxoviridae viruses can be pneumonia viruses (RSV), paramyxoviruses (PIV). Parapneumoviruses can be measles viruses (such as measles). Pneumoviruses can be respiratory syncytial virus (RSV), bovine respiratory syncytial virus, pneumonia virus of mice or turkey rhinotracheitis virus. Paramyxoviruses can be parainfluenza viruses (PIV) types 1-4, mumps, Sendai virus, simian virus 5, bovine parainfluenza virus, Nipah virus, Henipa virus or Newcastle disease virus. Poxviridae can be smallpox virus, such as major smallpox and variola. Metapneumoviruses can be human metapneumovirus (hMPV) or avian metapneumovirus. Measles virus can be measles. Picornaviruses can be enteroviruses, rhinoviruses, hepadnaviruses, diechoviruses, cardioviruses and foot-and-mouth disease virus. The enterovirus may be a poliovirus type 1, type 2, or type 3, a coxsackie A virus type 1 to 22 and type 24, a coxsackie B virus type 1 to type 6, an echovirus (ECHO) type 1 to type 9, type 11 to type 27, and type 29 to type 34, or an enterovirus type 68 to type 71. The bunyavirus may be a California encephalitis virus. The phlebovirus may be a Rift Valley fever virus. The nairovirus may be a Crimean-Congo hemorrhagic fever virus. The hepadnavirus may be a hepatitis A virus (HAV). The enveloped virus may be a rubella virus. The flavivirus may be a tick-borne encephalitis (TBE) virus, a dengue fever (type 1, type 2, type 3, or type 4) virus, a yellow fever virus, a Japanese encephalitis virus, a Kyosanur Forest virus, a West Nile encephalitis virus, a St. Louis encephalitis virus, a Russian spring-summer encephalitis virus, or a Powassan encephalitis virus. The pestivirus may be bovine viral diarrhea (BVDV), swine fever virus (CSFV), or border disease virus (BDV). The hepadnavirus may be hepatitis B virus or hepatitis C virus. The rhabdovirus may be rabies virus (Lyssavirus) or vesicular virus (VSV). The Caliciviridae may be a Norwalk virus, or a Norwalk-like virus, such as Hawaii virus and Snow Mountain virus. The coronavirus may be SARS-CoV-1, SARS-CoV-2, MERS, human respiratory coronavirus, avian infectious bronchitis (IBV), mouse hepatitis virus (MHV), or porcine transmissible gastroenteritis virus (TGEV). The retrovirus may be a tumor virus, a lentivirus, or a foamy virus. The reovirus may be an orthoreovirus, a rotavirus, a tobivirus, or a Korovirus. The parvovirus may be parvovirus B19. The human herpesvirus may be herpes simplex virus (HSV), varicella zoster virus (VZV), Epstein-Barr virus (EBV), cytomegalovirus (CMV), human herpesvirus 6 (HHV6), human herpesvirus 7 (HHV7), or human herpesvirus 8 (HHV8). The papovavirus may be a papillomavirus, a polyomavirus, an adenovirus, or an arenavirus.Preferably, the virus is selected from the group consisting of SARS-CoV, SARS CoV2, MERS or influenza.

[0075] However, in another embodiment, the microorganism can be a fungus. The fungus can be selected from the group consisting of dermatophytes, including: Epidermophyton floccosum, Microsporum audouinii, Microsporum canis, Microsporum equi, Microsporum gypseum, Microsporum suis, Trichophyton concentricum, Trichophyton equi, Trichophyton gallinarum, Trichophyton gypseum, Trichophyton giganteum, Trichophyton mentagrophytes, Trichophyton quinquenus, Trichophyton rubrum, Trichophyton schoenleinii, Trichophyton tonsurans, Trichophyton verrucosum, Trichophyton verrucosum var.album, var.disco ides, var.Ochraceum, violet trichophyton and / or dense block trichophyton; or selected from Aspergillus fumigatus, Aspergillus flavus, Aspergillus niger, Aspergillus nidulans, violet trichophyton and / or dense block trichophyton; or selected from Aspergillus fumigatus, Aspergillus flavus, Aspergillus niger, Aspergillus nidulans, Aspergillus terreus, Aspergillus saxonis, Aspergillus kava, Aspergillus glaucus, Schizosaccharomyces, Candida albicans, Candida enolase, Candida tropicalis, Candida glabrata, Candida krusei, Candida, Candida asteroides, Candida krusei Candida, Candida paraxensis, Portuguese Candida, Pseudotropical Candida, Candida guillimon, Cladosporium carinii, Coccidioides immitis, Blastomyces dermatitidis, Cryptococcus neoformans, Geotrichum capitis, Histoplasma capitis, Klebsiella pneumoniae, Microsporidia, Intracellulare, Diaphragma enterica and Enterocytosis bicipitans; Broccoli, Microsporidia, Microsporidia apis, Pleurotus ostreatus, Polyporus trachei, Vitacaceae, Paracoccidioides brasiliensis, Pneumocystis carinii, Pythium occulta, Pityrosporum ovale, Saccharomyces cerevisiae, Saccharomyces boulardii, Saccharomyces pombe, Eusporium, Sporothrix schenckii, Trichosporon albus, Toxoplasma, Penicillium marneffei, Malassezia, Chroma, Wang Ge La, Sporothrix, Frog dung mold, Ear mold, Rhizopus, Mucor, Absidia, Mortierella, Cunningham, Bottle mold, Alternaria, Curvularia, Helminthosporium, Fusarium, Aspergillus, Penicillium, Monollinia, Rhizoctonia, Paecilomyces, Pelvis and Cladosporium. Preferably, the fungus is selected from the group consisting of Aspergillus, Cryptococcus or Pneumocystis.

[0076] In yet another embodiment, the microorganism may be a protozoa. The protozoa may be selected from the group consisting of Entamoeba histolytica, Giardia lamblia, Cryptosporidium, Cyclospora cayetae and Toxoplasma gondii.

[0077] In one embodiment, the therapeutic agent is an antibiotic, an antiviral, an antifungal, or an antiprotozoal agent. Preferably, the therapeutic agent is an antibiotic.

[0078] Preferably, the selection of antimicrobial drugs may be based on bacterial Gram staining, in accordance with the protocols of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the Clinical and Laboratory Standards Institute (CLSI).Thus, the therapeutic agent is preferably an antimicrobial drug.

[0079] Thus, for Gram-negative bacteria, the antimicrobial drug may be selected from the group consisting of amikacin, gentamicin, ciprofloxacin, imipenem, meropenem, ertapenem, ceftazidime-avibactam, piperacillin-tazobactam, cefepime, ceftazidime, cefotaxime, ceftazidime-clavulanic acid, cefotaxime-clavulanic acid, ceftolozane-tazobactam, amoxicillin-clavulanic acid, ampicillin, fosfomycin, nitrofurantoin and colistin.

[0080] For Gram-positive bacteria, the antimicrobial drug may be selected from the group consisting of penicillin, ampicillin, cefoxitin, oxacillin, imipenem, vancomycin, linezolid, gentamicin, high-concentration gentamicin, levofloxacin, and daptomycin.

[0081] Preferably, the antifungal agent may be selected from the group consisting of caspofungin, micafungin, anidulafungin, posaconazole, voriconazole, flucytosine, amphotericin B, itraconazole, posaconazole and fluconazole.

[0082] Preferably, the antiviral agent may be selected from the group consisting of: a protease inhibitor, such as ritonavir, atazanavir or darunavir; a viral DNA polymerase inhibitor, such as acyclovir, tenofovir, valganciclovir or valacyclovir; and an integrase inhibitor, such as raltegravir.

[0083] Preferably, the antiprotozoal agent can be selected from the group consisting of metronidazole, atovaquone, benznidazole, dehydroemetine, eflornithine, emetine, fenbendazole, diiodoquinol, melarsoprol, nifurtimox, pentamidine, quinacrine, sodium gluconate, suramin and tinidazole.

[0084] The fluorescence analysis used in the method of the present invention can be a flow cytometric analysis or a laser scanning analysis. The flow cytometer can be equipped with a microplate reader for automatically analyzing each test reservoir. The flow cytometer can also be equipped with a blue laser and / or have 3 fluorescence channels.

[0085] In a preferred embodiment, the one or more flow cytometry parameters include forward scatter and / or side scatter and / or fluorescence parameters. The fluorescence scatter signal may be intensity, spectral distribution and / or cell count.

[0086] The fluorescent label may be selected from the group consisting of: nucleic acid stains, metabolic stains, membrane potential stains, probes for organelles, fluorescent tracers of cell morphology and fluid flow, probes for cell activity, proliferation and function, and / or probes for reactive oxygen species.

[0087] Preferably, the fluorescent label can be selected from the group consisting of acridine dyes, cyanine dyes, fluorone dyes, oxazine dyes, phenanthridine dyes or rhodamine dyes. Most preferably, the fluorescent label can be selected from the group consisting of: 5-cyano-2,3-dimethylphenyl tetrazolium (CTC), calcein AM, dihydrorhodamine 123, DIBAC4 (3), DioC2 (3), fluorescein diacetate, 5CFDA-AM, CFDA-SE, propidium iodide, SYTO 16 green fluorescence and nucleic acid dyes.

[0088] In a preferred embodiment, fluorescently labeled DiBAC4(3) is Figure 3A The indicated antibiotic combinations were used to test the susceptibility of Gram-negative bacteria to these antibiotics.

[0089] Preferably, the fluorescent marker propidium iodide (PI) is combined with the antibiotic imipenem to test the sensitivity of Pseudomonas to imipenem.

[0090] Most preferably, the fluorescent marker propidium iodide (PI) can be used with Figure 4A The indicated antibiotic combinations were used to test the susceptibility of Gram-positive bacteria to these antibiotics.

[0091] Fluorescently labeled DiOC2(3) (3,3'-diethyloxacarbocyanine iodide) can be used with Figure 4A The indicated antibiotic combinations were used to test the susceptibility of Gram-positive bacteria to these antibiotics.

[0092] Preferably, fluorescently labeled propidium iodide (PI) can be combined with colistin to test the sensitivity of Gram-positive bacteria to colistin.

[0093] In one embodiment, the method of the present invention may include at least one of:

[0094] (i) one or more first test reservoirs comprising a fluorescent marker / therapeutic agent combination,

[0095] (ii) one or more second positive control reservoirs, and

[0096] (iii) one or more third negative control reservoirs each containing the same fluorescent label, and optionally

[0097] (iv) one or more fourth autofluorescent control reservoirs in which neither fluorescent marker nor therapeutic agent is present.

[0098] In other words, preferably at least one combination of fluorescent marker / therapeutic agent (preferably fluorescent marker / antibiotic) is tested. In this set, the fluorescent markers are identical.

[0099] In another embodiment, the method of the first aspect comprises multiple groups:

[0100] (i) one or more first test reservoirs comprising a fluorescent marker / therapeutic agent combination,

[0101] (ii) one or more second positive control reservoirs, and

[0102] (iii) one or more third negative control reservoirs each containing the same fluorescent label, and optionally

[0103] (iv) one or more fourth autofluorescent control reservoirs in which neither fluorescent marker nor therapeutic agent is present.

[0104] In other words, preferably, at least two, three, four or more different combinations of fluorescent marker / therapeutic agent (preferably, fluorescent marker / antibiotic) are tested. Preferably, at least five, six, seven or more different combinations of fluorescent marker / therapeutic agent (preferably, fluorescent marker / antibiotic) are tested. In each group, the fluorescent marker is the same. However, the fluorescent marker can be the same or different between multiple groups. The number and type of fluorescent marker / therapeutic agent combinations can depend on whether Gram-negative bacteria or Gram-positive bacteria are detected.

[0105] The reservoir can be a container, a tube or a well. Preferably, the reservoir is a well. For example, the well can be a part of a plate, such as a 96-well plate.

[0106] In a second aspect of the present invention, a kit for use in the method of the first aspect is provided.

[0107] The kit of the present invention may be a plate comprising one or more first reservoirs, second reservoirs, third reservoirs and / or fourth reservoirs. Preferably, the plate may be a 96-well plate.

[0108] Advantageously, the inventors have carefully designed test panels optimized for the detection of various microorganisms. Each test panel includes a carefully selected combination of therapeutic agents / antibiotics and fluorescent markers, wherein each therapeutic agent / antibiotic and fluorescent marker / fluorescent dye combination is optimized to improve the accuracy of the reading. The present invention represents the first disclosure of a preset combination of drugs and fluorescent dyes in a test panel prior to culturing the microorganisms.

[0109] In one embodiment, the plate may be Figure 3A Preferably, the FASTgramneg board comprises Figure 3BThe well disclosed in . Therefore, preferably, the plate is configured to analyze Gram-negative bacteria. Preferably, in the plate for analyzing Gram-negative bacteria, the antibiotics ampicillin, amoxicillin-clavulanic acid, cefotaxime, ceftazidime, cefotaxime-clavulanic acid, ceftazidime-clavulanic acid, ceftazidime-clavulanic acid, ceftolozane-tazobactam, cefepime, cefoxitin, ceftazidime-avibactam, piperacillin-tazobactam, ciprofloxacin, gentamicin, amikacin, nitrofurantoin, fosfomycin, imipenem and meropenem are preferably combined with DIBAC. Preferably, imipenem is combined with PI (in another well).

[0110] In another embodiment, the plate may be Figure 4A Preferably, the FASTgrampos board comprises Figure 4B . Thus, preferably, the plate is configured to analyze Gram-positive bacteria. Preferably, in the plate for analyzing Gram-positive bacteria, the antibiotics ampicillin, cefoxitin, oxacillin, penicillin, vancomycin and imipenem are preferably combined with PI. Preferably, gentamicin, linezolid, daptomycin, levofloxacin are combined with DIOC.

[0111] In yet another embodiment, the plate may be Figure 5A Preferably, the FASTcolistin MIC plate comprises Figure 5B Preferably, the plate is thus configured for the analysis of Gram-negative bacteria. Preferably, in the plate for the analysis of Gram-negative bacteria, the colistin MIC is combined with the PI.

[0112] The inventors believe that the above-mentioned purification method of microorganisms is novel. As mentioned above, the present disclosure constitutes the first description of the use of density gradient solutions (such as histopaque-RTM) for purification, identification and / or diagnosis of microorganisms in microbiological assays. The inventors have demonstrated that this method is more effective than the standard physical separation used in the prior art because no cells are lost during the centrifugation process and the suspension is cleaner and therefore purer.

[0113] Therefore, in a third aspect of the present invention, there is provided a method for purifying microorganisms from a biological sample, comprising:

[0114] (i) obtaining a biological sample including a microorganism; and

[0115] (ii) contacting the biological sample with a density gradient solution to purify the microorganisms.

[0116] Therefore, in a fourth aspect, there is provided a use of a density gradient solution for purifying microorganisms from a biological sample.

[0117] The microorganism may be purified in the biological sample. The method may include a subsequent step of extracting the microorganism from the biological sample.

[0118] Preferably, the density gradient solution is histopaque (RTM-1077). TM The invention relates to a density gradient cell separation medium comprising Ficoll and sodium diatrizoate. Preferably, the biological sample and the density gradient are present in a 1:1 ratio.

[0119] After the step of contacting the biological sample with the density gradient solution, the sample preparation step preferably comprises centrifuging the sample, preferably for at least one minute, preferably at about 13,000 rpm. The sample preparation step comprises resuspending the resulting precipitate (including the purified microorganisms) in a culture medium. The culture medium is preferably a cation-adjusted broth, optionally about 1 ml of sterile filtered Mueller Hinton II cation-adjusted broth.

[0120] The method preferably comprises contacting the biological sample with a hemolytic agent prior to contacting the biological sample with the density gradient solution. Preferably, the hemolytic agent is configured to lyse any contaminating cells in the sample, such as contaminating host cells from the host from which the sample was collected, or debris present in the environmental sample. In embodiments where the sample comprises blood, preferably a blood culture, a hemolytic agent is preferably used. Figure 1 Scheme B disclosed in shows a preferred embodiment of the sample preparation step of the method when the biological sample is a blood sample.

[0121] In one embodiment, the hemolytic agent can be Triton TM X-100 (commonly known as Triton X-100). TM X-100 is a common nonionic surfactant and emulsifier, often used to solubilize proteins in biochemical applications. It is considered a relatively mild and non-denaturing detergent. It is used to lyse cells to extract proteins and organelles. It can also permeabilize living cell membranes for transfection, or for DNA extraction.

[0122] Preferably, Triton X-100 is used at a concentration between 0.1% and 3% (v / v), or between 0.2% and 2.5% (v / v), or between 0.3% and 2% (v / v), or between 0.4% and 1% (v / v), preferably about 0.5% (v / v). Preferably, the biological sample is contacted with the hemolytic agent (preferably Triton X-100) for at least 1 minute, 2 minutes or 5 minutes. Preferably, the biological sample is contacted with the hemolytic agent (preferably Triton X-100) for less than 2 hours, 1 hour, 30 minutes or less than 15 minutes. This step can be performed at room temperature. Therefore, preferably, the same preparation step includes contacting the biological sample with the hemolytic agent for five minutes at room temperature.

[0123] After contacting the biological sample with the hemolytic agent and before contacting the biological sample with the density gradient solution, the sample preparation step preferably includes centrifuging the sample, preferably for at least one minute, preferably at about 13000 rpm. Preferably, the sample preparation step then includes resuspending the resulting precipitate (with the microorganisms). Preferably, the precipitate is resuspended in a saline solution, optionally about 0.05 ml to 2 ml, 0.01 ml to 1 ml, or 0.25 ml to 0.75 ml of sterile filtered saline solution. Most preferably, the precipitate is resuspended in 0.5 ml of sterile filtered saline solution.

[0124] The hemolytic agent used in the extraction method allows the lysis of host cells, particularly red blood cells, and any potential debris that may be present in the biological sample, while retaining the microbial cells. The method described herein allows the purified microorganisms to accumulate toward the bottom of the tube, while the cell debris and host cells bound to the density gradient solution accumulate toward the top of the tube. Preferably, the method comprises extracting the microorganism from the sample.

[0125] The method can also include before the biological sample including the microorganism is introduced into each of the first reservoir, the second reservoir, the third reservoir and / or the fourth reservoir as described in the first aspect, identifying the microorganism. Genetic methods, microarrays, physical methods and / or mass spectrometry can be used to identify the microorganism. The genetic method can be quantitative polymerase chain reaction (PCR), immune PCR or a combination thereof. The microarray can be a DNA microarray, a protein microarray, an antibody microarray or a combination thereof. The physical method can be infrared spectroscopy and Raman spectroscopy or laser induced breakdown spectroscopy (LIBS). Mass spectrometry can be carried out by ICP mass spectrometer, DART mass spectrometer or MALDI-TOF Brucker.

[0126] Therefore, in a preferred embodiment, the extraction method of the first aspect comprises:

[0127] (i) obtaining a biological sample including a microorganism;

[0128] (ii) contacting the sample with a density gradient solution;

[0129] (iii) centrifuging the sample; and

[0130] (iv) resuspending the resulting pellet.

[0131] Preferably, between steps (i) and (ii), the extraction method further comprises:

[0132] (a) contacting a biological sample with a hemolytic agent;

[0133] (b) centrifuging the sample; and

[0134] (c) Optionally resuspend the resulting pellet.

[0135] Thus, in another aspect, there is provided a method for determining the sensitivity phenotype of a microorganism present in a biological sample to at least one therapeutic agent, the method comprising:

[0136] (i) Sample preparation steps, including:

[0137] (a) obtaining a biological sample including a microorganism;

[0138] (b) contacting the sample with a density gradient solution; and

[0139] (c) optionally identifying the microorganism.

[0140] (ii) introducing a biological sample comprising a microorganism into:

[0141] (d) one or more first test reservoirs,

[0142] (e) one or more second positive control reservoirs, and

[0143] (f) one or more third negative control reservoirs, wherein the negative control reservoirs comprise non-viable microorganisms;

[0144] (g) one or more fourth autofluorescent control reservoirs,

[0145] (iii) contacting the biological sample in the one or more first test reservoirs with at least one therapeutic agent;

[0146] (iv) contacting the biological sample in one or more of the first reservoir, the second reservoir, and the third reservoir with at least one fluorescent marker; and

[0147] (v) performing fluorescence analysis to obtain one or more fluorescence parameters of the biological sample in each of the reservoirs,

[0148] Wherein the sensitivity phenotype of the microorganism to at least one therapeutic agent is obtained by comparing one or more fluorescence parameters between the reservoirs.

[0149] Preferably, the density gradient solution is histopaque (RTM).

[0150] Preferably, the extraction method of the first aspect further comprises between steps (a) and (b):

[0151] (i) contacting the biological sample with a hemolytic agent.

[0152] In one embodiment, the hemolytic agent can be incubated with the biological sample for less than or at least 10 minutes, less than or at least 9 minutes, less than or at least 8 minutes, less than or at least 7 minutes, less than or at least 6 minutes, less than or at least 5 minutes, less than or at least 4 minutes, less than or at least 3 minutes, less than or at least 2 minutes, or less than or at least 1 minute.

[0153] In another embodiment, the hemolytic agent can be incubated with the biological sample for less than 30 seconds, 20 seconds, 10 seconds or 5 seconds. Preferably, the hemolytic agent can be incubated with the biological sample for less than 4 seconds, 3 seconds, 2 seconds or 1 second.

[0154] Preferably, the hemolytic agent is Triton-X100.

[0155] In another preferred embodiment, the hemolytic agent is Tergitol. Preferably, Tergitol is used at a concentration of 10%. Preferably, the biological sample is contacted with Tergitol and mixed (preferably by vortexing).

[0156] All features described herein (including any accompanying claims, abstract and drawings) and / or all steps of any method or process disclosed may be combined with any of the above aspects in any combination, except combinations in which at least some of the features and / or steps are mutually exclusive.

[0157] For a better understanding of the invention, and in order to show how embodiments of the invention may be carried into effect, reference will now be made, by way of example, to the accompanying drawings, in which:

[0158] Figure 1 Schematic diagrams showing two embodiments of sample extraction protocols (Protocol A and Protocol B).

[0159] Figure 2 is a summary table of chemicals tested for killing cells included in negative controls for fluorescent probes used in embodiments of the methods of the present invention.

[0160] Figure 3AShown is the layout of one embodiment of a FASTgramneg plate for testing Gram-negative bacteria according to the present invention.

[0161] Figure 3B Shows Figure 3A Summary table showing the composition of each well of the FASTgramneg plate.

[0162] Figure 4A A layout of one embodiment of a FASTgrampos plate for testing Gram-positive bacteria according to the present invention is disclosed.

[0163] Figure 4B Shows Figure 4A A summary table showing the composition of each well of a FASTgrampos plate is shown.

[0164] Figure 5A A layout of one embodiment of a FASTcolistin MIC plate for testing Gram-negative bacteria according to the present invention is disclosed.

[0165] Figure 5B Shows Figure 5A Summary table showing the composition of each well of the FASTcolistin MIC plate.

[0166] Fig. 6A Shown are the numbers of Gram-negative bacteria of each species correctly identified on MALDI-TOF from blood culture samples purified by the sample preparation steps of the present invention compared to the numbers obtained from colony forming units from overnight (24 h) subcultures of blood samples.

[0167] Figure 6B Shown are the numbers of Gram-positive bacteria of each species correctly identified on MALDI-TOF from blood culture samples purified by the sample preparation steps of the present invention compared to the numbers obtained from colony forming units from overnight (24 h) subcultures of blood samples. Example

[0168] The inventors have developed a novel method or test for determining the sensitivity phenotype of microorganisms (such as bacteria, fungi, viruses or protozoa) in a biological sample to at least one therapeutic agent (such as an antibiotic). The method is called the "FASTinov Susceptibility Test". The inventors have also developed a kit specifically designed for assessing antimicrobial susceptibility to several antibiotics by flow cytometry, called the "FASTinov Plate". As part of the sample preparation steps for the test and the kit, different microbial extraction and purification methods were tested to optimize sample purity for subsequent analysis on the plate. In the process, the inventors developed an optimized protocol that ensures optimal sample quality and purity.

[0169] To evaluate the robustness of their method, the inventors tested two different blood samples, each spiked with one of the thirty most common bacterial isolates typically seen in clinical isolates (from the FASTinov collection). Depending on the isolate analyzed, an optimized combination of fluorescent probes and antibiotics was used.

[0170] The inventors have also designed an innovative plate layout that includes the different optimization features of the present invention.

[0171] Materials and methods

[0172] (i) Sample preparation

[0173] microorganism

[0174] Thirty bacteria belonging to the FASTinov collection and representing the most common bacterial isolates found in clinical settings were selected for this study. These isolates consisted of ATCC and clinical strains. Among them, 10 isolates were Gram-negative bacilli, 10 were Gram-positive cocci in grape-like clusters (such as Staphylococcus spp.), and 10 were chains of Gram-positive cocci (Enterococcus spp.).

[0175] Sample of the study

[0176] Two types of blood cultures are studied:

[0177] (i) Bactec PLUS Aerobic / F, ref 442192(AR), and

[0178] (ii) LYTIC / 10ANAEROBIC / F ref 442265 (ANA) from Becton Dickinson

[0179] Both blood cultures were spiked (i.e. infected) with the selected bacteria at the FASTinov laboratory in Porto (Portugal) according to the protocol described in [2] with slight modifications as described below.

[0180] To prepare bacterial suspensions, previously frozen isolates were subcultured. Bacteria were grown overnight in Mueller-Hinton agar and the concentration was adjusted in phosphate-buffered saline (PBS). For this purpose, 2 × 10 3 bacterial cells / bottle, and 8 mL whole blood samples obtained from blood donors. Inoculated blood cultures (BC) were incubated on recommended BD equipment until marked positive. Blood culture bottles from BioMérieux were also tested. Urine samples from healthy donors were also inoculated with the same strains following the same protocol

[15] .

[0181] Extraction of microorganisms from samples

[0182] In order to initiate AST using the new FASTinov technology, a purified bacterial suspension is required from a clinical or veterinary sample. Figure 1 , developed two different protocols (Protocol A and Protocol B) for extracting bacteria from positive (i.e. infected) blood cultures and compared the number of viable cells recovered:

[0183] 1) Plan A

[0184] After vortexing the blood culture, place the vacuum blood collection silicone tube (BD Barricor TM Blood collection tubes, reference number 365056) are filled with approximately 5.5 ml and centrifuged at 1500 rpm for 5 minutes. The supernatant is discarded and the pellet is resuspended in 1 ml of sterile filtered (through a 0.22 micron filter) saline solution. One (1) ml of the suspension is transferred to an Eppendorf tube and centrifuged at 13000x rpm (11337g) for 1 minute; the supernatant is then discarded. One (1) ml of sterile filtered (through a 0.22 micron filter) Muller-Hinton cation adjusted broth (reference number BD 275730) is added to the Eppendorf tube and vortexed. Colony forming units (CFU) are then evaluated. This process is performed twice.

[0185] 2) Plan B

[0186] After vigorous vortexing of the blood culture, the culture without any additives is placed into a vacuum blood collection gel tube, such as a 2 ml tube ( Figure 1 50 μl of 10% (v / v) Triton X-100 lysis reagent was then added to the contents of the 1 ml vortex tube, vortexed, and incubated at room temperature for 5 minutes. The mixture was then centrifuged at preferably 13,000 rpm for 1 minute, the supernatant discarded, and the pellet resuspended in 0.5 ml of sterile filtered (through a 0.22 micron filter) saline solution. (Ref. 10771) Add new tube ( Figure 1 Preferably, add 0.5 ml of lysate to the 0.5 ml already in the tube. The cells were centrifuged at 13,000 rpm for about 1 minute and the supernatant was discarded. One (1) ml of sterile filtered (through a 0.22 micron filter) Muller Hinton II cation adjusted broth (reference number BD 275730) was added to the Eppendorf tube and vortexed. Colony forming units (CFU) were then assessed. This process was repeated twice.

[0187] Statistical analysis

[0188] The Wilcoxon signed rank test was used to evaluate the differences between CFU obtained from aerobic (AR) and anaerobic (ANA) blood culture (BC) bottles after extraction of microorganisms using protocol A and AR bottle protocols A and B. All experiments were performed twice, and the mean values ​​were calculated. If the p value was less than 0.05 (<0.05), it was considered to be significantly different. Statistical analysis was performed using IBM SPSS statistical software version 24.0.

[0189] Identification of the source of infection

[0190] The suspension obtained after treatment with TRITON X-100 and Histopaque was used to identify microorganisms by MALDI-TOF (Bruker) using the septityper mode. Alternatively, the samples purified by protocol B were further centrifuged at 13000 rpm to 15000 rpm for 1 minute. The resulting precipitate was then dried at room temperature or 37°C before inoculating the MALDI-TOF (Bruker). The detection accuracy obtained using the dried precipitate was compared with that of the overnight culture.

[0191] (ii) FASTinov Board Specifications

[0192] Optimization of different board components and processing times

[0193] The inventors designed an innovative plate for evaluating the antimicrobial susceptibility of different types of bacteria to several antibiotics by flow cytometry. Antibiotic / probe combinations were optimized for selected bacterial groups (e.g., Enterobacteriaceae, Pseudomonas, Acinetobacter, Staphylococcus, or Enterococcus) and a 96-well plate for Gram-positive bacteria (FASTgrampos—see Figure 4A and 4B ) and 96-well plates for Gram-negative bacteria (FASTgramneg-see Figure 3A and 3B The inventors carefully selected the probe / concentration / time that best separated susceptible and resistant strains among various fluorescent probes available on the market.

[0194] To detect some resistance mechanisms, the Gram-negative panel includes drugs such as ceftazidime-clavulanic acid and cefotaxime-clavulanic acid for ESBL, cefoxitin for AmpC screening, and a low-value meropenem (0.25 ug / ml) for screening of carbapenemases.

[0195] Since the Gram-positive plate includes several concentrations of vancomycin, the MIC value (minimum inhibitory concentration) can be determined by flow cytometry and phenotype.

[0196] For colistin susceptibility, a separate plate was designed to provide phenotypes and MICs for Enterobacteriaceae, Pseudomonas, and Acinetobacter spp. The FASTcolistin MIC plate is Figure 5A and 5B As shown. The inventors strategically developed the antibiotic sequences and their order of appearance on the FASTgrampos and FASTgramneg plates. Furthermore, the inventors implemented optimal washing between each well, aiming to reduce carry-over effects discovered during the development phase. If not managed, such carry-over effects can produce harmful results such as false sensitivity, which in turn can lead to significant errors. In addition, two controls are included on the plates to ensure valid sensitivity readouts: (i) a positive control (untreated cells) which is typically required in microbial antimicrobial susceptibility testing, and (ii) a negative control (dead cells) to control for probe activity, which is typically used in cytometry assays but not in microbiology assays. This novel addition brings an innovative twist to the new inventors' plates (see Figure 2 ).

[0197] Moreover, these controls ensure that only viable (and not non-viable) microorganisms are considered in the sensitivity assessment. Non-viable microorganisms cannot respond to therapeutic agents. If they are included in the sensitivity assessment, the microorganism may be falsely resistant to all therapeutic agents, which corresponds to a false negative / diagnosis and a "big mistake", resulting in the wrong treatment being administered. Similarly, if the fluorescent probe is not present or performs poorly, the effect of the therapeutic on the microorganism will be difficult or impossible to assess. Therefore, the addition of the novel negative controls significantly improves the accuracy of AST.

[0198] (iii) Running AST with the newly designed board

[0199] To run AST using the new board, the inventors implemented the following steps:

[0200] Microbial selection

[0201] A large number of ATCC bacteria were selected for this study. Fifteen (15) Gram-negative rods were selected, including Escherichia coli ATCC 25922, Escherichia coli ATCC 8739, Escherichia coli ATCC 35218, Escherichia coli BAA 2425, Klebsiella pneumoniae ATCC 13443, Klebsiella pneumoniae BAA 1705, Klebsiella pneumoniae ATCC 700603, Klebsiella pneumoniae BAA 1706, Enterobacter aerogenes ATCC 13048, Serratia marcescens ATCC 14756, Providencia ritteri BAA 2525, Pseudomonas aeruginosa 27853, Pseudomonas aeruginosa BAA 2108, and Acinetobacter baumannii BAA 1709. Ten (10) additional Gram-positive cocci were selected from the grapes in the grape-like cluster, including Staphylococcus aureus 29213, Staphylococcus aureus 43300, Staphylococcus aureus 700698, Staphylococcus epidermidis 35984); 5 Gram-positive cocci chains were screened, including Enterococcus faecalis 29212, Enterococcus faecalis 51299, Enterococcus faecium 700221, Enterococcus casei 700668, Enterococcus gallinarum 49608. These bacteria are the most important and common bacteria found in clinical settings. The distribution of bacteria on each plate is summarized in Tables 1, 2 and 4 below.

[0202] Table 1: Species distribution of Gram-negative bacteria studied on the FASTgramneg kit

[0203]

[0204]

[0205] Table 2: Species distribution of Gram-positive bacteria studied on the FASTgrampos kit

[0206] Total blood cultures Staphylococcus 112 Staphylococcus aureus 47 Staphylococcus epidermidis 47 Staphylococcus hominis 15 Staphylococcus capitis 1 Staphylococcus lugdunensis 1 Hemolytic Staphylococcus 1 Enterococcus 87 Enterococcus faecalis 54 Enterococcus faecium 27 Enterococcus gallinarum 4 Enterococcus casei 1 Enterococcus raffinose 1 Total Gram-positive bacteria 199

[0207] Table 3: Species distribution of Gram-negative bacteria studied on the FASTcolistin MIC kit

[0208] Total blood cultures Escherichia coli 131 Escherichia coli 24 Klebsiella pneumoniae 60 Klebsiella aerogenes 2 Serratia marcescens 3 Providencia reuteri 1 Proteus mirabilis 4 Enterobacter cloacae 24 Enterobacter aerogenes 1 Enterobacter kobe 1 Enterobacter hallii 1 Citrobacter cohnii 1 Citrobacter freundii 5 Morganella morganii 4 Non-fermentation tank 123 Pseudomonas aeruginosa 59 Acinetobacter baumannii 64 Total Gram-negative bacteria 254

[0209] Analyze samples

[0210] Blood cultures (Bactec PLUS Aerobic / F from Becton Dickinson, ref 442192) were spiked with selected bacteria at the FASTinov laboratory in Porto (Portugal) according to the protocol described in [2] with slight modifications as previously described. Inoculated blood cultures (BC) were incubated on the recommended BD equipment until marked positive. Urine samples were inoculated with the same strains following the same protocol, thus placing urinary tract infection diagnosis under the potential use of the newly designed plates for a wide range of antibiotics.

[0211] Drug / fluorescent dye combinations

[0212] According to the microbial recognition patterns (see Tables 4 and 5 below), the most important antimicrobial drugs at breakpoint concentrations based on EUCAST and CLSI protocols were selected for testing on different samples, preferably blood culture and urine samples prepared as described above. Different fluorescent probes were tested at different concentrations; the lower concentration of each probe was selected, which showed the best discrimination between untreated cells and dead cells (indicating sensitivity).

[0213] Table 4: List of drugs included on the FASTgramneg for each group of microorganisms

[0214]

[0215] *Regarding Enterobacteriaceae, according to EUCAST and CLSI protocols, only applies to E. coli

[0216] #Used to determine the resistance mechanism

[0217] Table 5: List of drugs included in the FASTgrampos for each group of microorganisms

[0218]

[0219]

[0220] * Regarding Staphylococci, according to the EUCAST protocol, only Staphylococcus aureus is applicable

[0221] **Not suitable for Staphylococcus epidermidis

[0222] ***For use only with Staphylococcus epidermidis

[0223] ****MIC value of Staphylococcus aureus

[0224] #Regarding Enterococci, only applies to Enterococcus faecalis

[0225] Comparison

[0226] To ensure the viability of the strains and the activity of the probes, autofluorescence control wells (untreated and unstained cells), positive control or activity control wells (untreated and stained with each fluorescent probe) and negative control wells (stained dead cells, responsible for the positive control of the fluorescent dye) were carefully distributed in the plate. Different methods of negative controls were tested at different concentrations, stained with different probes, and compared in terms of flow cytometric analysis (see Figures 3-5).

[0227] Specific layout of the board

[0228] The plate includes a first well for autofluorescence control, followed by a positive control well, stained with the probe without any antibiotic. Antibiotics are always placed on the plate from lower to higher concentrations and bind to the probe. In the flow cytometer acquisition template, a three (3) second backwash is arranged between analysis wells for the same drug; and a twenty (20) second backwash is performed between wells for different drugs. Each well is mixed individually for three (3) seconds. Drugs (such as antibiotics) that show the highest fluorescence intensity when incubated with sensitive strains are intentionally placed at the end of the plate. For example, given that the FASTgrampos plate has two different fluorescent probes, a second autofluorescence well and a control stained with the second probe are included before staining the drug with the second probe (see one of the plates shown in the plate layout Figure 3-5). A carryover study is performed to determine that the specificity of the fluorescence reading corresponds to the actual labeled cells, rather than nonspecific or background fluorescence signals (see Figure 3-5).

[0229] Drying board performance and comparison

[0230] All optimizations were performed on freshly produced plates, and freeze-drying and drying processes were tested to obtain a product that was stable at room temperature. Antimicrobial drugs were quantified using microdilution and HPLC on samples that were stable at room temperature, and fluorescence activity was assessed by flow cytometry. Real-time stability studies were performed.

[0231] Plate inoculation and incubation

[0232] After sample preparation, a bacterial suspension at a MacFarland optical density of 0.5 was prepared in sterile saline solution and diluted in Mueller Hinton II cation-adjusted broth (BD 275730). 6 Up to 1x10 7 The optimal value is between 10 cells / ml. Incubate the cells at 37°C with shaking for 1 hour.

[0233] Flow cytometric analysis

[0234] For this analysis, the flow cytometer had the following specifications: equipped with a blue laser (488 nm; output: 50 mW; beam spot size: 5 x 80 μm);

[0235] There are 3 fluorescence channels: 525 / 40BP, 585 / 42BP and 690 / 50BP; and

[0236] Equipped with a microplate reader for automated analysis of each plate.

[0237] The settings for Enterobacter, Acinetobacter, Pseudomonas, Staphylococcus and Enterococcus were optimized. Parameters such as cell fluorescence intensity, cell number obtained in the wells and cell light scattering information were recorded, and cells treated with antibiotics were systematically compared with untreated cells (positive control). Using the analysis template of the inventor (FASTinov), the plate was analyzed, and the bioFast software including a proprietary algorithm was used to record data and generate reports. Validation criteria such as the survival rate of the strain (positive control) and the activity of the probe (negative control) were thoughtfully included. In addition, the number of events on the optimization gate (representing the analysis area of ​​bacteria) was also specifically included as a validation criterion. The minimum number of cells required to verify this test was required.

[0238] Reference Method

[0239] To evaluate the phenotypic results obtained by flow cytometric analysis, all isolates underwent antimicrobial susceptibility determination by disk diffusion as described in the reference protocols of EUCAST[3] and CLSI[4]. For colistin (for Gram-negative bacteria) and vancomycin (for staphylococci), the method used to determine antimicrobial susceptibility was broth microdilution[5]. Broth microdilution was also performed for meropenem because it was necessary to know whether the MIC was higher than the 0.25 μg / ml that might be required for screening for carbapenemases[6]. The standard method was performed using the same inoculum as that used for spiked blood cultures. Quality control of the reference method was also performed according to the recommendations of EUCAST and CLSI.

[0240] Data analysis

[0241] Will The results of the test were sensitive (S), intermediate (I) and resistant Results were compared with reference disk diffusion methods and / or MIC values ​​determined by microdilution.

[0242] (iv) Performance Evaluation

[0243] Verification location

[0244] Two locations are used to verify different kits (FASTgrampos, FASTgramneg and FASTcolistin MIC) that are derived directly from positive blood cultures at the FASTinov laboratory in Porto (Portugal), using spiked blood cultures and blood cultures from patients at the Ramon y Cajal Hospital in Madrid (Spain).

[0245] Bacterial strains

[0246] A total of 256 Gram-negative bacilli were studied on the FASTgramneg kit (180 at FASTinov and 81 at Ramon y Cajal Hospital) and 199 Gram-positive bacteria were studied on the FASTgrampos kit (131 at FASTinov and 68 at Ramon y Cajal Hospital). Different species of Enterobacteriaceae, Pseudomonas and Acinetobacter were studied, as well as Staphylococci and Enterococci. FASTPolistinMIC was performed at FASTinov and Ramon y Cajal Hospitals.

[0247] Antimicrobial Susceptibility Testing Using Reference Methods

[0248] All strains were classified as S, I, or R according to the reference method. The MICs of vancomycin and colistin were determined. Screening for the presence of ESBLs on group I Enterobacteriaceae, ESBLs on group II Enterobacteriaceae, and the presence of AmpC and carbapenemases according to the EUCAST protocol for detecting resistance mechanisms were also performed.

[0249] Antimicrobial susceptibility testing using FASTinov kits (FASTgramneg, FASTgrampos, and FASTcolistin MIC)

[0250] Following the sample preparation protocol optimized by the inventors (FASTinov), i.e., protocol B for extracting bacteria from blood cultures described above, the samples were inoculated on the newly designed FASTinov plates and analyzed by flow cytometry, and the antimicrobial susceptibility results were obtained and compared with the reference method.

[0251] Data analysis

[0252] Where applicable, class agreement (CA) and essential agreement (EA) were calculated, and quantitative errors were defined according to the standard of ISO 20776-2 (18). Errors were classified as mild (mE), severe (ME), and very severe (VME). Proportion of agreement (PA), sensitivity, and specificity for detecting ESBLs in group I Enterobacteriaceae and screening for pAmpC, carbapenemases, and ESBLs in group II Enterobacteriaceae were also performed. Disk diffusion or microdilution (in cases where the disk diffusion test is not recommended or a quantitative test is required) were considered as the gold standard method and were used for comparison with the FASTinov kit results. Data analysis incorporated expert rules for species with intrinsic resistance to a certain drug (EUCAST) on its software.

[0253] (v) MALDI-TOF identification

[0254] According to the instructions and protocol for use of the FASTinov AST kit described above and the resulting bacterial suspensions, a total of 364 patients’ positive blood cultures were processed, of which 177 were positive for Gram-positive cocci and 187 were positive for Gram-negative bacilli. However, for Maldi-TOF identification, the sample preparation step uses Tergitol TM (Sigma) as shown below.

[0255] 1 ml of blood culture was placed in a sterile microcentrifuge tube and mixed with 50 μL of Tergitol (10% v / v), then vortexed and centrifuged at 13000 rpm for 1 minute. The supernatant was discarded and the resulting precipitate was resuspended with 1 ml of sterile saline. The mixture was vortexed until the precipitate was completely resuspended. 1 ml of this suspension was gently transferred to a 500 μL Repeat the centrifugation, then discard the supernatant, wash the resulting pellet with saline solution, then centrifuge again and discard the supernatant. Repeat the wash-centrifuge-discard cycle using sterile water and dry the final pellet at 37°C for 5-10 minutes.

[0256] The final precipitate was applied directly to the MALDI-TOF target plate with two spots per sample (i.e., in duplicate) using a wooden toothpick, and 1 μl of α-cyano-4-hydroxycinnamic acid (CHCA) matrix was added after the spot dried. The target plate was placed in the Bruker MALDI Biotyper and the analysis was started using the Sepsityper sample type option on the device. The results were compared with the colonies on the next day and the ID score was recorded.

[0257] (vi) Validation studies

[0258] Study design and sample collection.

[0259] The study was conducted simultaneously at three sites. These sites included:

[0260] First location: FASTinov location in Porto (Portugal)

[0261] At this site, the study used BACTEC blood bottles from Becton Dickinson (BD) spiked with well-characterized strains belonging to the FASTinov bacterial collection and ATCC strains from the American Type Culture Collection (ATCC) and incubated according to the protocol described in reference 2 until a positive result for infection was recorded.

[0262] The second location: Ramon et Cajal Hospital in Madrid, a hospital with approximately 1,000 beds.

[0263] Positive blood cultures (BACTEC, BD) from consecutive patients were included in the study between November 2021 and February 2022 (one sample per patient).

[0264] Third location: Centro Hospitalar S. (CHSJ), Porto, a university hospital with about 1,000 beds.

[0265] Positive blood cultures (BACTEC, BD) from consecutive patients were included in the study (one sample per patient). These blood cultures were collected from patients with suspected bloodstream infection between March and July 2022.

[0266] Positive blood cultures were identified by matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry (Bruker Daltonics, Germany) using the septityper mode. The high diversity of species was investigated and reported in Table 12. All tested strains were subcultured on blood agar plates to assess purity, and then reference susceptibility tests were performed on each strain, and the strains were subsequently frozen at -80°C according to the approved research code. Polymicrobial blood cultures were excluded from the study.

[0267] Ethical considerations.

[0268] This study was approved by the Ethics Committee of the Ramón y Cajal University Hospital (reference number 161 / 17) and the Ethics Committee of the CentroHospitalar S. Joao (reference number 284 / 21).

[0269] FASTinov test.

[0270] Positive blood cultures identified by Maldi-Tof at each site were processed according to the rapid AST according to the instructions for use of the FASTinov kit described above.

[0271] Cell damage analysis

[0272] To assess antibiotic-induced cell damage, flow cytometry analysis was performed using a Beckman Coulter CytoFlex model B3-R0-V3 (at sites 1 and 2) and a DxFlex (at site 3), both equipped with a blue laser (488 nm; output power 50 mW; spot size 5 × 80 μm). These instruments have three fluorescence channels: 525 / 40BP, 585 / 42BP, and 690 / 50BP. The DxFlex was equipped with a microplate reader for automated analysis of each plate. The flow cytometer was used in slow mode.

[0273] Software Analysis

[0274] Data analysis was performed using proprietary software with an algorithm defined by FASTinov, and the results were considered on the basis of comparison with reference methods.

[0275] Timing of the instrument

[0276] Given that the equipment can only analyze one plate at a time, the time the plate spends inside the instrument is the bottleneck of the assay. Therefore, the time required for flow cytometry analysis of each sample depends only on the type of bacteria and the sensitivity protocol used (i.e., EUCAST or CLSI). This time is a fixed value assigned to the instrument because it is programmed to analyze a fixed volume, acquire in slow mode, and automatically wash between wells.

[0277] Repeatability

[0278] The 10 inoculum samples used at the FASTinov sites were also inoculated at each site to include a variety of phenotypes at each site and to calculate inter-laboratory reproducibility.

[0279] Reference Method (RM)

[0280] Positive blood cultures were spiked into blood agar and colonies were identified based on disk diffusion and / or MIC values ​​determined by microdilution and submitted to antimicrobial susceptibility testing. The results were analyzed using the latest EUCAST breakpoint table and the CLSI's M100 (29th edition) breakpoint table.

[0281] Example 1 - Optimization of sample preparation steps

[0282] Regarding sample preparation, Figure 1 and Figure 2 Shown are the number of CFU recovered from aerobic (AR) and anaerobic (ANA) blood culture (BC) bottles using protocol A. For Gram-negative bacteria, the final number of microorganisms (CFU) obtained from AR and ANA bottles was not statistically different and was always >1x10 8 / ml(>1x10 8 / ml).

[0283] In contrast, significant differences were observed for Staphylococcus spp., where cell numbers measured in ANA bottles outperformed those measured in AR bottles for 8 of 10 different strains grown in AR bottles. The number of recovered Staphylococcus spp. cells was insufficient to inoculate FASTinov plates (a minimum of 1x10 7 For Enterococcus spp., both AR and ANA bottles had enough cells to inoculate FASTinov plates (>1x10 7 / ml), the number measured in the AR bottle was slightly higher. The data presented in Table 6 below correspond to the average of the results obtained for 2 bottles / each strain.

[0284] Table 6: Positive cultures grown from aerobic (AR) and anaerobic (ANA) blood culture bottles after extraction using Protocol A The cell concentration obtained

[0285]

[0286] A – For Gram-negative bacteria, the final number of microorganisms measured from growth in AR and ANA bottles was not statistically different and was always >1x10 8 / mL.

[0287] B1- Gram-positive Staphylococci were observed to have significant differences, with cell numbers measured in ANA bottles being superior to those measured in AR bottles; for 8 of the 10 different strains grown in AR bottles, the cell numbers measured were insufficient to inoculate FAST plates (minimum 1x10 6 / mL)

[0288] B2 – For Gram-positive Enterococci, both AR and ANA bottles have sufficient number of cells to inoculate the FAST plate (>1x10 7 / mL), the measured quantity of AR bottle was slightly higher.

[0289] The data presented here correspond to the mean of the results obtained from 2 bottles / each strain. Cell counts were performed by flow cytometry in predefined gates.

[0290] Comparing protocols A and B, the CFUs were higher in all cases (Gram-negative bacilli and Gram-positive cocci) than in protocol B, as shown in Table 7 below. For Staphylococci, the difference was even more dramatic, as sufficient cells could be obtained for the FASTinov test using protocol B and the AR BC bottles.

[0291] Table 7: Extraction from positive cultures grown in aerobic (AR) and blood culture bottles following extraction using protocols A and B. Cell concentration

[0292]

[0293] Protocol B recovered significantly more microorganisms than protocol A; this was particularly relevant for Staphylococci inoculated on the AR blood bottles.

[0294] In view of the above results, in order to simplify the method and provide a single sample preparation protocol that can be applied to all microorganisms and specimens, protocol B was selected for all future cases. Figure 1As shown, protocol B involves the use of Triton X-100 followed by the use of Histopaque. The bacteria contained in the bacterial suspension obtained before the preparation of the subsequent suspension at a MacFarland optical density of 0.5 were correctly identified using the MALDI-TOF Bruker.

[0295] Similar to the colonies observed from overnight blood cultures, dried samples purified by protocol B provided a high percentage of accurate identification of microorganisms: 100% for Gram-negative bacteria (Enterobacter, Pseudomonas, and Acinetobacter), as shown in Figure 2. Fig. 6A As shown in Figure 2, Gram-positive cocci (Staphylococcus and Enterococcus) accounted for 98.3%. Figure 6B shown.

[0296] This extraction protocol was used in BioMérieux blood culture bottles and positive urine (>10 6 CFU / ml) also achieved excellent results.

[0297] Example 2 - Selection of fluorescent probes

[0298] The sensitivity results for each drug / antibiotic were compared with the reference method. Several combinations between drug / fluorescent probe gave good results. Table 8 below summarizes the fluorescent probes tested in combination with the antibiotics disclosed in Tables 3 and 4.

[0299] Table 8: Fluorescent probes for combined antibiotic testing

[0300] Fluorescent dyes concentration 5-Cyano-2,3-dimethylphenyltetrazolyl (CTC) 4mM Calcein AM 2.5 μg / mL Dihydrorhodamine 123 2.5 to 10 μM Bis(1,3-dibutylbarbituric acid)trimethyloxonol (DiBAC4(3)) 0.5 / 1 / 2 μg / mL 3,3'-Diethyloxacarbocyanine iodide (DiOC2(3)) 0.03μM Fluorescein diacetate (FDA) 0.5, 1 and 2 μM 5-Carboxyfluorescein diacetate, acetoxymethyl ester (5-CFDA, AM) 0.5, 1 and 2 μM Carboxyfluorescein acetoacetate succinimidyl ester (CFDA-SE) 0.5, 1 and 2 μM Propidium iodide 1 μg / mL <![CDATA[SYTO TM 16 Green fluorescent nucleic acid dyes]]> 5, 10, 20 μM

[0301] 5-Cyano-2,3-dimethylphenyltetrazolium (CTC), calcein AM, dihydrorhodamine 123, DIBAC4(3), DioC2(3), fluorescein diacetate, 5CFDA-AM, CFDA-SE, propidium iodide, SYTO 16 green fluorescence and nucleic acid stains.

[0302] However, in order to reduce the number of controls, the number of selected fluorescent dyes is reduced to a minimum, as each probe requires a positive control and a negative control. In addition, the manufacturing development process becomes more complicated when the number of probes in the plate increases. In addition, the inventors must consider which probes will make the plate stable at room temperature, as well as the best drug / fluorescent dye combination. These processes are unique and complex, and therefore require extensive research and development.

[0303] For the FASTgramneg plates used to test Gram-negative bacteria, surprisingly, in the case of Pseudomonas, 1 μg / ml of DiBAC4 (3) was identified as a probe that stained for all drugs except imipenem. Therefore, for this particular case, 1 μg / ml of propidium iodide (PI) gave better results (see Figure 3A and Figure 3B FASTgramneg board layout in ).

[0304] For the FASTgrampos plates used to test Gram-positive bacteria, there are two types of fluorescent probes: Figure 4A and Figure 4B ), 1 μg / ml PI and 0.06 uM 3,3'-diethyloxacarbocyanine iodide (DiOC2(3)) were selected.

[0305] For the FASTcolistin MIC plate for testing Gram-negative bacteria, 1 μg / ml of PI is optimal (see Figure 5A and Figure 5B Untreated cells were stained with these fluorescent probes (positive controls), and the highest benzydamine concentration tested was chosen as a negative control for all probes.

[0306] Example 3 - Determination of bacterial susceptibility using the FASTinov method and associated kits

[0307] Validation of all processes, including the extraction protocol (Protocol B) and inoculation of the optimized plates, was evaluated at both sites, and the CA, EA, and the number and type of errors found during validation are shown in Table 9 .

[0308] Table 9: Overall performance data related to FASTgramneg, FASTgrampos and FASTcolistin MIC

[0309]

[0310] n-number of strains

[0311] EA(%) - basic agreement percentage

[0312] CA(%) - Class Agreement Percentage

[0313] mE - slight error; ME - severe error; VME - very severe error

[0314] FASTcolistin MIC

[0315]

[0316] Example 4 - MALDI-TOF Identification

[0317] The agreement ratio (PA) of the FASTinov sample preparation method compared with the reference was about 95.6% overall. The detailed results are presented in Tables 10 and 11.

[0318] Table 10: Colony identification in Gram-positive strains compared with the FASTinov sample preparation method (reference). Summary results of MALDI-TOF identification of the prepared samples.

[0319]

[0320] Table 11: Colony identification in Gram-negative strains using the FASTinov sample preparation method compared to colony identification (reference) Summary results of MALDI-TOF identification of the prepared samples.

[0321]

[0322] As shown in the table, no misidentifications were found, but no identification was obtained in 16 of the total 364 cases; the scores were very similar to the colonies and were divided by group. The meaning of the score values ​​was defined using the cutoff values ​​of the Sepsityper sample type according to the Bruker MALDI Biotyper. The main findings of this study are as follows (the higher the score, the better the result):

[0323] Gram-positive: 14.3% of cases were observed to have a score <1.59;

[0324] 4.1% of cases scored between 1.6-1.79

[0325] 81.6% of cases had a score >1.8.

[0326] Gram-negative: A higher score means:

[0327] It was observed that 15.6% of cases had a score <1.59;

[0328] There were no cases with scores between 1.6-1.79

[0329] 84.4% of cases had a score >1.8.

[0330] These results demonstrate that the FASTinov ultrafast AST sample preparation method can be used for parallel MALDI-TOF identification and ultrafast AST, achieving efficient diagnosis while providing excellent accuracy for both Gram-positive and Gram-negative bacteria.

[0331] Example 5 - Validation Study

[0332] A total of 651 blood cultures were studied from the three sites, of which 348 isolates were Gram-negative and 303 were Gram-positive. Table 12 shows the distribution of isolates by species at each site.

[0333] Table 12: Test strains in the FASTgramneg kit and FASTgrampos in the FASTinov laboratory in Porto (Site 1), Ramon y Cajal Hospital in Madrid (Site 2) and Centro Hospitalar S. (Location 3) The distribution of each location.

[0334]

[0335]

[0336]

[0337] Based on the analysis of results obtained from a multisite study according to EUCAST / CLSI guidelines, the sensitivity and specificity of this test were above 90%, as shown in Table 13. According to EUCAST / CLSI, the reproducibility of the FASTgramneg plate was 96.8% / 95% and that of the FASTgrampos plate was 95.1% / 95.1%.

[0338] Table 13: Sensitivity and specificity according to EUCAST and CLSI protocols of the FASTinov kit compared with the reference method opposite sex.

[0339]

[0340] The time required for the flow cytometer software bioFAST to read the FASTinov plate depends on the number and concentration of drugs tested for each microorganism and the selected protocol. The recorded time values ​​are reported in Table 14 below. The shortest time was 9 minutes for Acinetobacter according to the EUCAST protocol, while the longest time was 47 minutes for Enterobacter according to CLSI.

[0341] Table 14 Time required for flow cytometry to read FASTinov plates; according to bioFAST software

[0342] Bacteria Type EUCAST CLSI Enterobacteriaceae 39 minutes 47 minutes Pseudomonas 15 minutes 27 minutes Acinetobacter 9 minutes 23 minutes Staphylococcus 27 minutes 29 minutes Enterococcus 20 minutes 20 minutes

[0343] Very serious outcome (VME)

[0344] The details of VME are shown in Table 15. A greater number of strains (4 strains each) were observed for piperacillin / tazobactam and ceftolozane / tazobactam. The CA was 100% for amoxicillin / clavulanic acid (EUCAST) and ceftazidime / avibactam and amikacin (both on EUCAST / CLSI).

[0345] Table 15: The number of patients who received treatment at each site (site 1 - FASTinov, Porto; site 2 - Ramon et Cajal Hospital, Madrid; Location 3 - Centro HospitalarS. Porto) using FASTgramneg Very severe results (VME) obtained with the FASTgrampos kit

[0346]

[0347]

[0348] Results observed on the FASTgramneg kit

[0349] The overall classification agreement (CA) of the FASTgramneg kit was >95% and the error was <1.5%.

[0350] In the reference method (RM), there were 53 ESBL positive cases in Enterobacteriaceae group I, and the sensitivity and specificity of the FASTinov test were 96.2% and 100%, respectively, and the PA was 99.0%. Regarding the screening of Enterobacteriaceae group II ESBL, 13 cases were positive, with a sensitivity, specificity of 100%, and a PA of 100%. For the screening of plasmid AmpC (Enterobacteriaceae group I), in the RM, 38 cases were positive, with a sensitivity and specificity and a concordance ratio (PA) of 100%. Among them, 52 strains were positive for carbapenemase (MIC of meropenem>0.25ug / ml), and the FASTinov test showed a sensitivity of 96.2% (there were 2 false negatives for strains with a MIC of 0.5ug / ml), a specificity of 96.7%, and a PA of 96.6%.

[0351] Table 16 FASTgramneg results obtained for a total of 3 locations compared with the reference method

[0352]

[0353]

[0354] FASTgrampos Kit

[0355] The sensitivity and specificity of the Gram-positive kit analyzed according to the EUCAST guidelines were >95%, and the CA was >95% (Table 17). The CA of all tested drugs was >90%. ME and mE were also low.

[0356] Table 17 FASTgrampos results obtained for a total of 3 locations compared with the reference method

[0357]

[0358] The essential agreement (EA) of the vancomycin MIC assay against S. aureus was 100% with a bias of -30%, which is at the lower limit recommended by ISO 20776-2:2021.

[0359] The MIC distribution of the tested S. aureus is shown in Table 18. The FASTinov method generally provides one-fold higher dilution than the standard method.

[0360] Table 18: Staphylococcus aureus obtained on the FASTgrampos kit and broth microdilution (reference method) Distribution, basic agreement (EA%) and deviation calculation of MIC values ​​of bacteria to vancomycin.

[0361]

[0362] Tables 19-24 below provide the results obtained for each individual site.

[0363] Table 19: Total Fastgramneg performed at FASTionv (Porto)

[0364]

[0365] Table 20: Total Fastgrampos performed in FASTionv (Porto)

[0366]

[0367]

[0368] Table 21: Total Fastgramneg performed at Ramonet Cajal Hospital (Madrid)

[0369]

[0370]

[0371] Table 22: Total Fastgrampos performed at Ramonet Cajal Hospital (Madrid)

[0372]

[0373] Table 23: In S. Total Fastgramneg performed by Hospital (Porto)

[0374]

[0375]

[0376] Table 24: In S. Total Fastgrampos performed by Hospital (Porto)

[0377]

[0378]

[0379] Discussion and Conclusion

[0380] Hospitals are in urgent need of rapid antimicrobial testing, especially in critical situations such as sepsis. The inventors have developed a highly innovative and pioneering antimicrobial susceptibility testing (AST) assessment technology, as well as an improved protocol for the efficient extraction of microorganisms from clinical samples at concentrations that make them easy to analyze by flow cytometry. A concentration of at least 1x10 7 / ml of clean (with as little debris as possible) microbial suspension to perform the novel and rapid AST test. The inventors started using barricot tubes (Scheme A above) to extract microorganisms (bacteria or fungi) from positive blood cultures or urine cultures or any other biological samples. During this process, some bacterial cells were lost during centrifugation (bacterial cells formed a pellet together with human / animal cells and debris at the bottom of the test tube), although in most cases a suspension containing enough cells could be obtained. The most controversial case was the observation of Staphylococci in aerobic blood cultures, probably due to their common conformation in liquid culture media: grape-like clusters would reach the bottom by centrifugation. However, this did not happen in anaerobic blood cultures, probably because they include saponins, which can form large grape-like clusters during division.

[0381] Knowing that Staphylococcus is one of the most common microorganisms recovered from blood cultures in clinical settings, and that anaerobic blood bottles are the most common blood cultures in laboratories, the inventors developed an improved extraction process, namely, Scheme B above, such as Figure 1 As shown, this protocol has been proven to be very efficient for the extraction of microorganisms, especially Staphylococci.

[0382] It can form a concentration gradient of blood components, especially for the separation of white blood cells (in The suspension is separated from the red blood cells (at the top) by the red blood cells (at the bottom). When the blood sample contains microorganisms, they go to the bottom with the red blood cells. Previously, lysed blood culture samples (treated with a lysing agent such as Triton X-100 or Tergitol) were used. After centrifugation, a clean, concentrated suspension of microorganisms is obtained. Protocol B is particularly useful when the microorganism to be extracted is Staphylococcus. However, when attempting to extract any and all microbial species, aerobic or anaerobic blood cultures in bottles (BD or BioMérieux) can be used, and surprisingly, even other biological samples such as urine, bronchial secretions and cerebrospinal fluid can be used. Therefore, this is the first report of the new extraction protocol developed by the inventors.

[0383] With respect to the plates (i.e., kits) developed by the inventors, several fluorescent probes can be used for each antimicrobial drug. However, the inventors decided to use the same probes in most cases as much as possible, because each probe used requires a corresponding positive control and a negative control. Therefore, if several probes are included, this will have a negative impact and extend the time required to perform the test and generate antibiotic sensitivity readings. In addition, the process of drying each probe is complicated, so the inventors chose to include as few probes as possible.

[0384] Three controls were designed for this assay. The first is a positive control, which is traditionally used in microbiology assays to ensure the viability of the strain. The other two controls, an autofluorescence control and a negative control, are commonly used in cytometry assays to confirm the presence of staining (i.e., the difference between stained and unstained cells) and that the probes are staining the cells correctly. This is the first report of their use in microbiology assays.

[0385] So, in summary, the assay includes positive controls to determine bacterial survival. The positive control is achieved with bacterial cells that have not been treated with antibiotics, but exposed to a fluorescent stain, which was confirmed during development to not affect bacterial cell survival. In the autofluorescence control, the bacterial cells were not treated with antibiotics and not stained with a fluorescent probe. In the negative control, the bacterial cells were exposed to a killing agent and stained with a fluorescent probe. This is key to controlling the quality of the fluorescent compound to determine that when the bacteria are damaged or even dead, the fluorescent agent will mark them.

[0386] Likewise, this is the first report of an innovative layout of the plate designed by the inventors. However, it should be understood that the reported plate layout may be altered within the scope of the present invention for a variety of reasons, such as the introduction of new drugs, changes in CLSI and EUCAST breakpoints, the introduction of different fluorescent dyes, or even changes in drug sequences.

[0387] The outstanding results reported in Table 9 for CA, EA, and a few VME and ME are in compliance with FDA and ISO 20776-2 recommendations, indicating that the methods, tests, and kits described herein could revolutionize antimicrobial therapy worldwide with significant clinical and public health impacts.

[0388] As shown in multi-site studies, The kit consistently provides ultra-rapid AST (less than 2 hours) with high accuracy and reproducibility, improving timely diagnosis of sepsis patients and thus impacting their clinical outcomes.

[0389] References

[0390] 1.WO2012 / 164547A1.Kit and method of detecting the resistantmicroorganism to a therapeutic agent.

[0391] 2.Puttaswamy S,et al 2011.Novel Electrical Method for Early Detectionof Viable Bacteria in Blood Cultures,Journal of Clinical MicrobiologyVolume49,Issue 6,June 2011,Pages 2286-2289.3.

[0392] 3.Clinical and Laboratory Standards Institute.2021.PerformanceStandards for Antimicrobial Susceptibility Testing:Twenty-eight InformationalSupplement M100.

[0393] 4.A novel flow cytometric assay for rapid detection of extended-spectrum beta-lactamases.aria-Ramos I,Espinar MJ,Rocha R,Santos-Antunes J,Rodrigues AG,Cantón R,Pina-Vaz C.Clin Microbiol Infect.2013Jan;19(1):E8-E15

[0394] 5.Evaluation of FASTinov Ultrarapid Flow Cytometry AntimicrobialSusceptibility Testing Directly from Positive Blood Cultures.Silva-Dias A,Pérez-Viso B,Martins-Oliveira I,Gomes R,Rodrigues AG,Cantón R,Pina-Vaz C.J ClinMicrobiol.2021Sep 20;59(10):e0054421.doi:10.1128 / JCM.00544-21.Epub 2021.

[0395] 6.A Rapid Flow Cytometric Antimicrobial Susceptibility Assay(FASTvet)for Veterinary Use-Preliminary Data.Andrade FF,Gomes R,Martins-Oliveira I,Dias A,Rodrigues AG,Pina-Vaz C.Front Microbiol.2020Aug 7;11:1944.doi:10.3389 / fmicb.2020.01944.eCollection 2020.

[0396] 7.Ultra-rapid flow cytometry assay for colistin MIC determination inEnterobacterales,Pseudomonas aeruginosa and Acinetobacter baumannii.Fonseca ESilva D,Andrade FF,Gomes R,Silva-Dias A,Martins-Oliveira I,Pérez-Viso B,RamosMH,Rodrigues AG,Cantón R,Pina-Vaz C.Clin Microbiol Infect.2020 Nov;26(11):1559.e1-1559.e4.doi:10.1016 / j.cmi.2020.08.019.Epub 2020.

[0397] 8.ISO,Standardization tIOf.In vitro diagnostic medical devices—Clinical performance studies using specimens from human subjects—Good studypractice.ISO 20916:2019.1 ed:ISO(the International Organization forStandardization);2019.

[0398] 9.ISO,Standardization tIOf.ISO 20776:2006 Clinical laboratory testingand in vitro diagnostic test systems:Susceptibility testing of infectiousagents and evaluation of performance of antimicrobial susceptibility testdevices.

[0399] 10.European Committee on Antimicrobial Susceptibility Testing.EUCAST:Clinical breakpoints and dosing of antibiotics 2021.

[0400] 11.M07:Dilution AST for Aerobically Grown Bacteria-CLSI 2021.

[0401] 12.Testing ECoAS.EUCAST;guidelines for detection of resistancemechanisms and specific resistances of clinical and / or epidemiologicalimportance.2.0 ed2017.

[0402] 13.Antifungal activity of local anesthetics against Candidaspecies. CPina-Vaz 1 , AGRodrigues , F Sansonetty , JMartinez-De-Oliveira , AFFonseca , PA Infect Dis Obstet Gynecol.

[0403] 14.Benzydamine Bactericidal Effect Results from a Permanent CellMembrane Lesion.Ferdinando F Andrade1,2*,Irene Pina-Vaz3,4,Acácio GRodrigues1,4,Cidália Pina-Vaz1,3,Infect Dis Diag Treat 5:169.

[0404] 15.Roos V.Ulett GC,Schembri MA and Klemm P.The asymptomaticbacteriuria Escherichia coli strain 83972 outcompetes uropathogenic E.colistains in human urine.Infect Immun 74(1),615-624.

Claims

1. A method for determining the sensitivity phenotype of a microorganism present in a biological sample to at least one therapeutic agent, the method comprising: (i) introducing a biological sample including a microorganism into: (a) one or more first test reservoirs, (b) one or more second positive control reservoirs, and (c) one or more third negative control reservoirs, wherein the negative control reservoirs comprise non-viable microorganisms; (ii) contacting the biological sample in the one or more first test reservoirs with at least one therapeutic agent; (iii) contacting the biological sample in the one or more of the first reservoir, the second reservoir, and the third reservoir with at least one fluorescent marker; and (iv) performing fluorescence analysis to obtain one or more fluorescence parameters of the biological sample in each of the reservoirs, The sensitivity phenotype of the microorganism to the at least one therapeutic agent is obtained by comparing one or more fluorescence parameters between the reservoirs.

2. The method of claim 1, wherein the one or more first test reservoirs comprise live or viable microorganisms, optionally at least 60%, 70% or 80% viable cells.

3. The method of claim 1 or 2, wherein the one or more second positive control reservoirs comprise live or viable microorganisms, optionally at least 60%, 70% or 80% viable cells.

4. A method according to any of the preceding claims, wherein the one or more third negative control reservoirs are rendered non-viable by exposure to a cell-killing agent, optionally wherein the one or more third negative control reservoirs comprise the cell-killing agent, optionally wherein the one or more third negative control reservoirs comprise at least 60%, 70% or 80% non-viable cells.

5. The method according to claim 4, wherein the cell-killing agent is selected from the group consisting of ethanol, 2-phenoxyethanol, citric acid and benzydamine hydrochloride. The method according to claim 5 , wherein the cell killing agent is benzydamine hydrochloride.

7. The method according to any one of the preceding claims, wherein the sensitivity phenotype is sensitive, intermediate or resistant.

8. The method of any of the preceding claims, wherein the method further comprises introducing the biological sample into one or more fourth autofluorescence control reservoirs, the reservoirs not comprising the therapeutic agent or the fluorescent marker.

9. The method of claim 8, wherein the one or more fourth autofluorescent control reservoirs comprise live or viable microorganisms, optionally at least 60%, 70% or 80% viable cells.

10. The method according to any one of the preceding claims, wherein the method further comprises a sample preparation step.

11. The method of claim 10, wherein the sample preparation step comprises purifying the microorganism from the biological sample prior to introducing the microorganism into each of the first reservoir, the second reservoir, the third reservoir and / or optionally the fourth reservoir.

12. The method according to claim 10 or 11, wherein the sample preparation step comprises: (i) obtaining the biological sample comprising the microorganism; and (ii) contacting the sample with a density gradient solution.

13. The method of claim 12, wherein the density gradient solution is histopaque (RTM).

14. The method according to claim 12 or 13, wherein the sample preparation step comprises contacting the biological sample with a hemolytic agent before contacting the biological sample with the density gradient solution, optionally wherein the hemolytic agent is Triton X-100 or Tergitol.

15. The method according to any one of claims 10 to 14, wherein the sample preparation step further comprises: (iii) identifying said microorganism prior to introducing said biological sample comprising said microorganism into each of said one or more first reservoirs, second reservoirs, third reservoirs and / or optionally said fourth reservoirs.

16. The method according to claim 15, wherein the microorganism is identified using mass spectrometry, preferably mass spectrometry MALDI-TOF, optionally wherein the biological sample is dried before identifying the microorganism, optionally wherein the drying of the biological sample is achieved by a centrifugation step and / or an air drying process.

17. The method according to any of the preceding claims, wherein the biological sample is of human, animal or environmental origin, preferably wherein the sample is of human origin.

18. The method according to claim 17, wherein the biological sample of human origin is a urine sample or a blood sample, preferably a blood sample.

19. The method according to any one of the preceding claims, wherein the microorganism is selected from the group consisting of bacteria, viruses, fungi or protozoa, preferably wherein the microorganism is a bacteria.

20. The method according to any one of the preceding claims, wherein the therapeutic agent is selected from the group consisting of antibiotics, antivirals, antifungals and antiprotozoals; preferably wherein the therapeutic agent is an antibiotic.

21. The method according to any one of the preceding claims, wherein the fluorescence analysis is flow cytometry or laser scanning analysis, preferably wherein the fluorescence analysis is flow cytometry.

22. The method according to any one of the preceding claims, wherein the one or more flow cytometric parameters comprise forward scatter and / or side scatter and / or fluorescence parameters.

23. The method of claim 22, wherein the fluorescence scatter signal is intensity, spectral distribution and / or cell count.

24. The method according to any one of the preceding claims, wherein the fluorescent label is selected from the group consisting of acridine dyes, cyanine dyes, fluorone dyes, oxazine dyes, phenanthridinium dyes and rhodamine dyes.

25. The method according to any one of the preceding claims, wherein the fluorescent label is selected from the group consisting of 5-cyano-2,3-ditolyl tetrazolium (CTC), calcein AM, dihydrorhodamine 123, DIBAC4(3), DioC2(3), fluorescein diacetate, 5CFDA-AM, CFDA-SE, propidium iodide, SYTO 16 green fluorescence and nucleic acid dyes.

26. A method according to any preceding claim, wherein the reservoir is a container, a tube or a well, preferably wherein the reservoir is a well.

27. A kit for use in the method according to any one of claims 1-26.

28. The kit according to claim 27, wherein the kit is a plate comprising the one or more first reservoir, second reservoir, third reservoir and / or fourth reservoir, optionally wherein the plate is a 96-well plate.

29. The kit of claim 27 or 28, wherein the plate is configured for analysis of Gram-negative bacteria.

30. A kit according to claim 29, wherein the plate is a plate substantially as shown in Figure 3A or Figure 5A.

31. The kit of claim 27 or 28, wherein the plate is configured for analysis of Gram-positive bacteria.

32. A kit according to claim 31, wherein the plate is a plate substantially as shown in Figure 4A.

33. A method for purifying a microorganism from a biological sample, comprising: (i) obtaining a biological sample including a microorganism; and (ii) contacting the sample with a density gradient solution to purify the microorganism.

34. The method of claim 33, wherein the method further comprises contacting the biological sample with a hemolytic agent prior to contacting the sample with the density gradient solution.

35. The method of claim 33, wherein the biological sample is a blood sample.

36. The method of claim 34 or 35, wherein the hemolytic agent is Triton X-100 or Tergitol.

37. The method of any one of claims 33-36, wherein the density gradient solution is histopaque (RTM).

38. Use of density gradient solution for purifying microorganisms from biological samples.

39. The use according to claim 38, wherein the density gradient solution is histopaque (RTM).